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ABSTRACT
Thirty-nine participants, 17 in a chronic steroid group (CS) and 22 in a steroid avoidance
group (SA) were compared with regard to their cognitive performance. It was predicted
that participants in the SA group would outperform those in the CS group on the
domains of declarative memory and complex attention. For participants in the CS group,
age and prednisone duration but not dose were predicted to significantly contribute to
the score on the declarative memory composite score. Group-wise comparisons were
not significant for the domains of declarative memory, complex attention, or processing
speed. The CS group outperformed the SA group on the domain of simple attention.
Regression analysis, for the CS group, indicated that duration of dialysis prior to
transplant accounted for a significant portion of the variance in the declarative memory
composite score. After controlling for months since transplant, prednisone dose also
accounted for approximately 26% of the variance in the declarative memory score.
Patients maintained on 5 mg of prednisone performed relatively worse than those
maintained on 2.5 mg with regard to declarative memory. The clinical and theoretical
significance of the findings relative to recent literature is discussed.
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Renal Transplant and Cognition 1
I. INTRODUCTION
The management and treatment of patients with Chronic Kidney Disease (CKD)
has evolved tremendously over the past 30 years (Pliskin, Kolbasa, Hart, & Umans,
2001). During that time, there has been a concurrent progression of knowledge about
the neuropsychological correlates of CKD. Investigations conducted during the 1960s
and 1970s examined the neurocognitive effects of uremia (blood poisoning) and chronic
renal (relating to the kidneys) failure. Studies in the late 1970s and 1980s focused on
the neurocognitive sequelae of chronic hemodialysis (HD) and peritoneal dialysis (PD)
(Pliskin et al., 2001). As renal transplantation has become a more viable option for
many patients with CKD, there is an interest in the neurocognitive effects of this
procedure.
In accordance with the recent interest in the neurocognitive sequelae of renal
transplantation, the prospective investigation that is presented in this paper was carried
out with the specific objective of examining the cognitive impact of long-term, low-dose
prednisone. The clinical importance of the investigation is highlighted by the fact that
several patient groups may be exposed to long-term, low-dose corticosteroids including
recipients of solid organ transplantation and those with certain rheumatic conditions. In
the present study, two groups of post renal transplant recipients on steroid avoidance or
maintenance protocols were compared with regard to their performances on the
cognitive domains of declarative memory, simple attention, complex attention and
processing speed. The relative contribution of patient age, duration of prednisone and
dose of prednisone to predicting variance in a declarative memory score for participants
in the steroid maintenance condition was also examined. Prior to describing the
investigation, the literature on cognitive functioning as it relates to CKD and steroid
therapy is reviewed.
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II. REVIEW OF THE LITERATURE
The objective of this portion of the paper is to provide the reader with information
regarding neuropsychological functioning in CKD. More specifically, the majority of the
introduction will focus on neuropsychological functioning as it pertains to
immunosuppressive medications (specifically steroids) utilized to manage patients who
are post-renal transplant. A list of terms that are used throughout this paper is
presented in the Appendix A.
In order to present information in a structured and logical manner, this portion of
the paper is divided into six sections. Information about basic renal physiology and
measures of renal function is presented in Section One. Section Two covers the
classification, epidemiology, and common etiologies of CKD. Dialysis and the
neuropsychological correlates of dialysis are covered in Section Three. Section Four
examines transplantation and the neuropsychological correlates of transplantation.
Section Five introduces the reader to post-transplant immunosuppression and the
related neuropsychological findings. Section Six provides the reader with a relatively
detailed overview of the neuropsychological literature as it relates to a specific
component of the immunosuppressive regimen, namely corticosteroids.

Section One- Basic Renal Physiology and Measures of Renal Function
The kidneys are bean-shaped organs, each about the size of a fist, located near
the middle of the back, just below the rib cage. Each kidney is composed of
approximately one million nephrons (the functional unit of the kidney). Each nephron in
turn is composed of a compact package of interconnected capillary loops (glomeruli)
surrounded by a capsule (Bowman's capsule), which is attached to a series of long
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tubules (Mohanram & Toto, 2005). Substances are filtered from blood that enters the
glomeruli. Re-absorption of nutrients from the filtrate occurs in the glomeruli and the
tubules. The filtrate is then excreted as urine, and the blood is returned to circulation
through the renal veins. Together, the glomeruli and tubules compose the working mass
of the kidneys (Danovitch, 2005; Mohanram & Toto, 2005).
In general, the kidneys are responsible for regulating urinary output relative to
dietary salt and water intake (Eaton & Pooler, 2004). The input of water into our bodies
is extremely variable because many of the foods and beverages we consume are
comprised, to varying degrees, of water. The kidneys respond by adjusting the output of
water in the urine, thereby maintaining constant total body water content (Lieberthal &
Nigam, 2000). Minerals such as sodium, potassium, and magnesium are also, to
varying degrees, components of the foods and drinks we consume. As with water, our
kidneys excrete these minerals at a highly variable rate that, in sum, matches input.
In addition to the liquids and foods we consume, our bodies are continuously
forming end-products as a result of metabolism. In most cases these end-products
serve no function and are harmful at high concentrations. Removal of urea (by-product
of protein metabolism), uric acid (by-product of nucleic acid metabolism), creatinine (byproduct of muscle metabolism) and other metabolites is one of the foremost functions of
the kidneys (Lieberthal & Nigam, 2000). Failure of the kidneys to remove these
substances from the blood results in waste buildup, leading eventually to uremia. In its
advanced stages uremia is characterized by fatigue, anorexia, nausea, drowsiness,
impaired concentration, and generalized nonspecific complaints, that may progress to
frank encephalopathy with possible seizures (Pliskin et al., 2001).
Blood pressure depends substantially on blood volume that is in turn regulated
by the kidneys' maintenance of sodium and water balance. Thus, the kidneys participate
in regulation of blood pressure through volume control (Eaton & Pooler, 2004).
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The kidneys serve a variety of important endocrine functions. Erythropoietin is a
peptide hormone that is involved in the control of erythrocyte (red blood cell) production
by the bone marrow. The kidneys produce the vast majority of erythropoietin, although
the liver also secretes small amounts (Lee et al., 2004). The stimulus for secretion of
erythropoietin is a reduction of partial pressure of oxygen in the kidneys. This can occur,
for example, in anemia (a condition in which blood is deficient in erythrocytes,
hemoglobin, or total blood volume), arterial hypoxia (deficiency of oxygen in arterial
blood), and inadequate renal blood flow. In these situations, erythropoietin stimulates
the bone marrow to increase production of erythrocytes (Marsh et al., 1991; Pliskin et al.,
2001).
The active form of vitamin D (1, 25- dihydroxyvitamin D3) is produced in the
kidneys. Production of vitamin D in turn helps to regulate calcium, phosphorus and
parathyroid hormone levels (Burrows-Hudson, 2005). Finally, the kidneys are
responsible to a large degree for gluconeogenesis (synthesis of glucose from noncarbohydrate sources such as protein and triglycerides) (Eaton & Pooler, 2004).
The kidneys serve a wide array of functions, all facilitated by their capacity to
transport water and solutes between the blood flowing through the kidneys and the
lumina of the tubules (Lierberthal & Nigam, 2000). Substances that are in excess, or are
not needed, are eventually excreted in the urine. Thus, the kidney is the organ chiefly
responsible for the maintenance of liquid homeostasis within the human body.
Clinically, several techniques are used to assess renal function. The variety of
measurement techniques become more important when considering that CKD is
commonly silent in the early stages (Mohanram & Toto, 2005; Pliskin et al., 2001).
Glomerular Filtration Rate (GFR) is one of the most commonly used measures of global
renal function. It is a measure of the efficiency with which the kidneys filter and clear
substances from the blood (Harvey, 2003). Operationally, it is defined as the clearance

Renal Transplant and Cognition 5
by filtration of a marker from the plasma by the kidneys, usually within a specified
amount of time (Burrows-Hudson, 2005; El Nahas & Bello, 2005; Harvey, 2003). An
ideal marker is one that is freely filtered, not protein bound, readily available clinically,
and safe and inexpensive (Burrows-Hudson, 2005; Mohanram & Toto, 2005).
Theoretically, although there are many such markers available, only markers that are
typically used in clinical settings will be discussed in this paper.
The two most popular endogenous markers of kidney function are serum
creatinine and blood urea nitrogen. Creatinine is a non-toxic by-product of muscle
metabolism (Kidney/Disease Outcome Quality Initiative (K/DOQI), 2002). Serum
creatinine is used as an endogenous marker because its rate of production is relatively
stable (roughly 10-20 mg creatinine/kg body weight per day), it is not protein bound, and
is freely filtered (Pliskin et al., 2001). Serum creatinine is influenced by age, body
weight, and gender as all three of these are related to muscle mass. Recent formulas
take these factors into account when calculating GFR based on serum creatinine
(K/DOQI, 2002; El Nahas & Bello, 2005). Another indirect guage of GFR involves
prediction based on creatinine clearance. In this method, the amount of creatinine
excreted in the urine is compared to the level in the plasma over a 24-hour period.
However, because portions of the tubules also secrete a small amount of creatinine,
creatinine clearance frequently leads to an overestimation of GFR (Levey et al., 2003).
However, GFR estimation from 24-hour creatinine clearance is frequently used for
people with exceptional diets (i.e., vegetarians, those taking creatine supplements).
Serum creatinine combined with modification equations that control for age, mass, and
gender appears to be the most commonly used clinical method for calculation of GFR
(Burrows-Hudson, 2005; K/DOQI, 2002; Levey et al., 2003).
Blood urea nitrogen is a by-product of protein metabolism that serves as a useful
clinical marker of renal function (K/DOQI, 2002). Blood urea nitrogen, which is normally
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approximately 10-20 mg/dl, is prone to inaccuracy depending on the patient's protein
intake and breakdown, which in turn is dependent on diet, liver function, and renal
function. Furthermore, while blood urea nitrogen increases with falling GFR (thus
providing a measure of renal integrity), it is also selectively retained whenever blood flow
to the kidneys is compromised, as in the case of dehydration or congestive heart failure
(K/DOQI, 2002). Therefore, the degree of blood urea nitrogen elevation is typically an
imperfect marker of renal failure because it depends on non-GFR related factors.
However, measurement of blood urea nitrogen clearance (the ratio of its excretion rate
to its concentration in the blood) typically provides a more conservative estimate of GFR
than does creatinine clearance (Mohanram & Toto, 2005).
Microalbuminuria and Proteinuria
Although both serum creatinine and blood urea nitrogen provide useful measures
for estimating GFR and overall renal integrity in normal individuals, there is some
evidence to indicate that they may not be sensitive enough when screening for CKD
(K/DOQI, 2002; El Nahas & Bello, 2005; Levey et al., 2003). This is particularly true in
the early stages, when renal function may be modestly compromised (Bishop, 2001;
Burrows-Hudson, 2005). Microalbuminuria is the leakage of small amounts of a blood
protein called albumin into the urine, and serves as a more sensitive indicator of early
renal dysfunction. As kidney function worsens, the amount of albumin and other
proteins in the urine increases due to a reduced ability to filter substances, leading to
proteinuria (K/DOQI, 2002). Albuminuria and subsequently proteinuria can both be
detected with the use of an inexpensive dipstick urinalysis. If this test indicates the
presence of CKD, management of the disease progresses to monitoring GFR (BurrowsHudson, 2005; Pliskin et al., 2001).
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Section Two- CKD, Classification, Epidemiology and Etiology
Classification
CKD classification has been improved by the adoption of the five tiered scheme
recently proposed by the National Kidney Foundation in its Kidney Disease Outcome
Quality Initiative (K/DOQI, 2002). The adoption of a universally accepted classification
scheme and associated terminology has allowed comparisons to be drawn across
various investigations. Prior to the publication of this scheme, communication between
scientists was hampered by the usage of various combinations of expressions referring
to the same idea. The scheme proposed by the National Kidney Foundation is
presented in Table 1 and has several elements.
First, the National Kidney Foundation has adopted the term CKD to refer to the
entire spectrum of disease that follows the initiation of kidney damage (Stages 1 and 2).
In their scheme CKD is defined as either kidney damage (as measured by increased
proteinuria, biopsy, or structural imaging) and/or decreased kidney function (as
measured by GFR<60 ml_/min/1.73m2 body surface area (bsa)) for three or more months
(Levey et al., 2003).
Second, the five tiered model ranges from occult kidney damage with well
preserved renal function (Stage 1), down to the level of renal failure requiring
replacement therapy (Stage 5). Notably, the National Kidney Foundation guidelines
point out that kidney failure is not synonymous with end-stage renal disease. End-stage
renal disease is an administrative term used to denote that a patient is being treated with
renal-replacement therapy (i.e., dialysis or transplantation). This is the condition for
payment for health care by the Medicare End-stage Renal Disease Program. As such,
the category of end-stage renal disease does not include patients with kidney failure who
are not being treated with dialysis or transplantation (Ganesh, Hulbert-Shearon, Port,
Eagle, & Stack, 2003; Levey et al., 2003).

i
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Third, according to the proposed criteria, a documented GFR below 60
mUmin/1.73m2 bsa, may by itself fulfill the definition of CKD without additional evidence
of underlying kidney damage. This cutoff for GFR was selected because it represents a
loss of half or more of the adult level of normal kidney function (Levey et al., 2003). It is
below this level that associated complications (e.g., uremia, anemia) typically occur
(Eustace & Coresh, 2005). Therefore, patients with a GFR between 60 and 89, without
evident kidney disease, are defined as having decreased GFR with or without
associated hypertension rather than CKD. This approach avoids potentially
misclassifying otherwise healthy elderly people with decreased GFRs without associated
evidence of kidney failure. Furthermore, it also helps to identify individuals who are
potentially at risk of developing CKD as a consequence of their lower baseline GFR
(Knight, Oesthun, Teng, Lazarus, & Curhan, 2003; Schaubel, Morrison, Desmeules,
Parsons, & Fenton, 1998; Stengel et al., 2003).
Fourth, stage five, which is denoted when GFR dips below 15 mL/min per 1.73m2
bsa, typically indicates the need for initiation of renal replacement therapy. In the United
States approximately 98% of patients begin dialysis when their GFR drops below this
level (Atkins, 2005; Jones, 2003).
Overall, the staging system proposed by the National Kidney Foundation focuses
primarily on the severity of kidney dysfunction rather than on diagnostic considerations.
As such, it acts to complement and in no way replaces traditional classification schemes
based on etiology. In fact, several investigations suggest that CKD stage, as outlined in
the guidelines set forth by the National Kidney Foundation, is an excellent measure of
severity and an accurate predictor of the risk of comorbidity and complications (El Nahas
& Bello, 2005; Knight et al., 2003; Levey, et al., 2003). Limitations to this classification
scheme have been pointed out. GFR tends to decline with age. However, little is known
about the causes of this decline, which may be due to CKD. If so, it may be more

Renal Transplant and Cognition 9
appropriate to classify individuals with GFRs between 60 and 89 ml_/min/1.73m2bsa
without apparent markers of kidney damage as having CKD rather than "decreased
GFR" (Jones, 2003; Levey, et al., 2003; Obrador, Pereira, & Kausz, 2002). The GFR
cut-off values for stages three to five were selected based on limited data with respect to
the relationship between complications and level of GFR. The K/DOQI work group has
called for further investigations to enable a refinement of these cutoffs.
Epidemiology
The prevalence and incidence of end-stage renal disease is rising worldwide as
reflected in the increasing numbers of individuals on renal replacement therapy (Atkins,
2005; Schaubel, et al., 1998). There is substantial evidence to suggest, at least in the
case of North America, that this is a result of the aging population and the pandemic of
Type II Diabetes (El Nahas & Bello, 2005; Himmelfarb, 2002; Knight et al., 2003). The
number of patients in the End-stage Renal Disease Medicare funded program in the
United States increased from approximately 10,000 beneficiaries in 1973 to 86,354 in
1983, to 340,261 in 1999 (Obrador et al., 2002). Furthermore, in the United States, the
number of people with kidney failure who are treated with dialysis and transplantation is
projected to increase from approximately 340,000 currently to 650,000 by the year 2010
(United States Renal Data Systems, (USRDS), 2000). There appears to be some
worldwide variability in the rates of renal replacement therapy, with higher rates in
developed countries. Specifically, between the years 2000 and 2003 incidence rates of
end-stage renal disease were 100, 135, and 330 new patients per million of the
population in the United Kingdom, Europe, and the United States respectively (El Nahas
& Bello, 2005). These rates appear to be much higher than in less developed countries
such as India, presumably because of the high cost of renal replacement therapy.
Furthermore, disparities in the incidence of end-stage renal disease within and between
more developed countries are likely to reflect the varying racial and ethnic mixes. For
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example, in the United States and Australia the annual incidence of end-stage renal
disease is substantially lower in white (94 and 250 per million/year respectively) than in
African-American (982 per million/year) people (El Nahas & Bello, 2005). The number of
patients with end-stage renal disease likely underestimates the entire burden of CKD,
because individuals in the earlier stages (i.e., 1 to 3) may often go undiagnosed or
misdiagnosed (Himelfarb, 2002; Lysaght, 2002).
In the United States, the most comprehensive examination of the epidemiology of
CKD was conducted through the Third National Health and Nutrition Examination Survey
(NHANES-III) (Jones, 2003). NHANES-III was a cross-sectional survey of the US
civilian non-institutionalized population that was implemented in two nationally
representative phases. Overall, more than 29,000 persons aged six months and older
participated in NHANES-III (Jones, 2003). In general, the findings of the NHANES-III
study implied that up to 11% of the United States general adult population (19 million
people) could have some degree of CKD, including more than 8 million individuals with
GFRs less than 60 ml_/min/1.73m2 bsa. The analysis also estimated that 5.9 million
people could have stage one CKD with normal renal function (Coresh, Astor, & Greene,
2003). One of the drawbacks associated with NHANES-III included serum creatinine
measurements that were taken at one point in time, which makes interpretation of some
results difficult. However, it provides some evidence suggesting that the problem of
CKD and subsequent end-stage renal disease, in the United States, is on the rise.
Other screening surveys of population representative samples in Australia, Japan, and
Europe have identified between 6 and 11 percent of individuals in those countries as
having some degree of CKD (Chadban, Briganti, & Kerr, 2003; Glassock, 2004; Stengel
et al., 2003).
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Etiology
CKD risk factors are broken down into several categories. The two most relevant
to the present discussion are susceptibility factors and initiation factors. The former are
those that increase the likelihood of kidney damage (e.g., old-age, family history of
CKD), while the latter are those that cause kidney damage (e.g., hypertension,
diabetes).
Diabetes mellitus is the leading cause of CKD in the United States, and patients
with diabetes account for approximately one-third of all cases of end-stage renal disease
(Ritz & Orth, 1999; Shumway & Gambert, 2002). Both Type 1 (formerly insulindependent diabetes mellitus) and Type 2 (formerly non-insulin-dependent diabetes
mellitus) diabetes can lead to diabetic nephropathy (microvascular complication leading
to deteriorating renal function). However, it is estimated that the global epidemic of Type
2 diabetes will be chiefly responsible for the global increase in CKD in the years to come
(Caramori & Mauer, 2003; Glassock, 2004). Clinically, the first evidence of nephropathy
in both disease subtypes is the presence of microalbuminuria. This is invariably
accompanied by the presence of an elevated GFR to more than 120 mL/min/1.73 m2
bsa. After 5-10 years, some patients will progress to macroalbuminuria with no initial
change in GFR. However, if no intervention is administered at this point, GFR will
continue to decline leading to end-stage renal disease (Dahm & Cooper, 2002; Harvey,
2003). The progression of the disease may be more pronounced in individuals with
Type 2 diabetes because they frequently have had the condition for some time before a
diagnosis is rendered (Shumway & Gambert, 2002). For example, a higher proportion of
individuals with Type 2 diabetes are found to have microalbuminuria and overt
nephropathy at the time they are diagnosed (Nesbitt, 2004). Furthermore, in 50% of
patients with Type 2 diabetes, hypertension is noted before microalbuminuria (National
High Blood Pressure Education Program, 2003).
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Several current theories exist as to how the hyperglycemic state produced by
diabetes results in diabetic nephropathy; however, many investigations illustrate that the
structural change that occurs in diabetes is a thickening of the glomerular basement
membrane resulting in the subsequent inability to efficiently regulate the filtration of
various substances such as albumin (Dahm & Cooper, 2002; Harvey, 2003; Ritz & Orth,
1999; Shumway & Gambert, 2002). Although there is currently no cure for diabetic
nephropathy, measures such as strict blood pressure control, exercise, and glycemic
control can slow the progression of the disease (Caramon & Mauer, 2003; Harvey,
2003).
Hypertension is unique in that it is both a cause and a consequence of CKD
(Adamzcak, Zeier, Dikow, & Ritz, 2002; Flack et al., 2003; Luft, 2004). Hypertension can
be defined as abnormally high arterial blood pressure (consistently greater than 140/90
millimeters of mercury) (Pease, 2002). Data suggest that hypertension is linked to CKD
and proteinuria, as well as kidney disease related mortality (Martins, Tareen, & Norris,
2002; Muirhead, 2001). Approximately 85% of persons with CKD (Stages 3 to 5) have
hypertension (Jones, 2003; Pontremoli et al., 2002).
The kidney has its own mechanism to regulate blood pressure, through the
release of a hormone called renin. The release of renin triggers a series of events in
several body systems eventuating in the conversion of the protein angiotensin I to
angiotensin II by angiotensin converting enzyme. Angiotensin II causes, amongst other
things, vasoconstriction of the blood vessels, and increased blood pressure (Adamczak,
et al., 2002). Since CKD affects blood perfusion within the glomeruli, it is frequently
accompanied, to some extent, by hypertension.
There are two theories regarding the pathophysiology of hypertension in
nephropathy. The first states that chronic hypertension results in a narrowing of preglomerular afferent arteries and arterioles, causing reduced blood flow to the glomeruli

Renal Transplant and Cognition 13
and the subsequent release of renin, resulting in increased blood pressure (Adamczak et
al., 2002). A second possibility is that chronic hypertension results in sclerosis
(hardening) of some glomeruli, causing increased pressure in the remaining glomeruli.
To compensate for reduced renal function, there is increased blood flow to the remaining
glomeruli and subsequent hyperfiltration, glomerular hypertension, and progressive
damage (Adamczak et al., 2002; Fervenza, 2005). These two mechanisms are not
mutually exclusive and likely occur, to some extent, simultaneously. Once CKD is
initiated, there is significant evidence to suggest that if uncontrolled, hypertension acts to
progressively worsen the course of the disease through increased proteinuria due to
reduced filtration capacity (Luft, 2004). Several studies have illustrated that
hypertensive diabetics (Types 1 and 2), and people with CKD and proteinuria lose
kidney function faster than those without proteinuria (Klein et. al., 1999; Luft, 2004;
Maschio, Marcantoni, & Bernich, 1999). Although there is no cure for hypertension in
CKD, strict blood pressure control, exercise, and dietary modifications are necessary to
reduce its impact. Furthermore, the efficacy of antihypertensive medications in reducing
the progression of microalbuminuria to subsequent proteinuria has been well
documented (Burrows, 2005; Dahm & Cooper, 2002; Glassock, 2004).
A smaller group of individuals experience CKD due to autoimmune diseases.
The two autoimmune diseases that most commonly lead to the development of CKD are
Systemic Lupus Erythematosus and Systemic Vasculitis. Systemic Lupus
Erythematosus is a disorder in which the body begins to produce antibodies against its
own tissues and organs. Common points of attack are the skin and various internal
organs such as the kidneys (Cameron, 1997). The most common complication of
Systemic Lupus Erythematosus leading to CKD is Lupus Nephritis. In Lupus Nephritis
there is an accumulation of antibodies in the kidney that subsequently lead to damage of
various internal kidney structures. Many investigators have reviewed the number of
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patients with Systemic Lupus Erythematosus who develop renal diseases, with overall
estimates ranging from 25% to 65% (Cameron, 1997; O'Callaghan, 2004). The nature
of the renal disease caused by Systemic Lupus Erythematosus is highly variable and
can result from several disease processes, all implicating the accumulation of antibodies
in various internal kidney structures but varying in severity. For example, tubular
interstitial disease involves an inflammation of the renal tubules and the spaces between
these tubules and the glomeruli. Patients with Lupus Nephritis may experience renal
associated problems similar to those of other CKD patients such as hypertension.
Management of the renal diseases in these patients requires a consideration of the
severity of the disease (Korbert, Lewis, Schwartz, et. al., 2000).
The Systemic Vaculitides are a group of rare diseases thought to be caused by
immune-mediated inflammation and necrosis of blood vessels, leading to eventual
occlusion and subsequent necrosis of the tissues fed by these vessels (Cunnard & Kelly,
2003). Examples of diseases in this category include: Wegener's Granulomatosis, Giant
Cell Arteritis, and Microscopic Polyangitis. Estimates of the incidence of primary
vasculitic disease are approximately 7-15 new cases per million per year (Watts,
Carruthers, & Scott, 1995). Treatment of the various Systemic Vasculitides ranges from
the use of Cyclophosphamide in patients with mild to moderate CKD to plasma
exchange in patients with disease severe enough to warrant HD (Pusey, Rees, & Evans,
1996). A range of other conditions, including scleroderma and rheumatoid arthritis, can
also be associated with renal pathology. However, renal involvement in such conditions
is not necessarily a common problem (Cunard & Kelly, 2003; O'Callaghan, 2004).
Currently, there are two treatment options for the person with severe CKD. The
first of these is dialysis, subclassified further as either HD or PD. Dialysis is still the first
treatment of choice worldwide for those with end-stage renal disease. More recently,
kidney transplantation has become a viable treatment option. These two treatment
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options and associated neuropsychological sequelae will be reviewed in the following
sections.

Section Three- Dialysis and its Neuropsychological Correlates
Dialysis
Dialysis continues to be the most highly utilized renal replacement therapy
worldwide. Strictly speaking, it is defined as the passage of molecules in solution by
diffusion across a semipermeable membrane (Yeun & Depner, 2005). Essential
elements of the process include a solvent that contains dissolved solutes and a
membrane that contains pores through which some or all of the solutes move by
diffusion. There are two types of dialysis, HD and PD.
The basic procedure in HD involves the removal of excess water and solutes
from blood that is passed along a semipermeable membrane within a dialysis filter, as
blood is passed through an extracorporeal circuit (Nesrallah, Blake, & Mendelssohn,
2005). Dialysis fluid circulates on the other side of this large surface area membrane,
allowing wastes to flow down their concentration gradients out of the blood and needed
molecules, such as calcium, to be delivered to the patient (Pliskin et al., 2001).
Adequate HD is that level of treatment that will minimize long-term mortality and
morbidity, be fiscally efficient, and most of all, provide patients the best possible quality
of life (Leypoldt, 2005). Currently, the most widely accepted measurement for HD
adequacy is (Kt/V) where K is the total cleared volume of urea, t is the total time of
dialysis, and V is the patient's total body water (Gotch & Sargent, 1985). HD is
considered adequate when Kt/V is at least 1.2 (Gotch & Sargent, 1985; N/KDOQI,
2002). HD sessions typically take place three times per week and last for 3 to 4 hours.
HD is sometimes referred to as intermittent dialysis, a label emphasizing the
accumulation of toxins that may take place between sessions (Pliskin et al., 2001).

Renal Transplant and Cognition 16
On the other hand, PD utilizes the patient's own highly vascular peritoneal
membrane as the semipermeable dialyzer and blood supply, with sterile dialysis fluid
installed directly into the abdominal cavity (Gokal & Mallick, 1999). Solutes, including
uremic wastes, potassium, and acids diffuse along their concentration gradients into this
fluid. Water is also transferred along this gradient. The net result is a translocation of
solute and fluid from blood into the dialysate. The dialysate is changed at regular
intervals so that the solutes are removed and the concentration and osmotic gradients
may be restored (Nesrallah, Blake, & Mendelssohn, 2005).
There are several types of PD including, Continuous Ambulatory PD (CAPD),
Continuous Cycling PD and Nocturnal Intermittent PD. The latter two are both
considered types of automated PD because dialysate solution is drained from the
abdomen through the aid of a machine rather than through manual means as in CAPD
(Gokal & Mallick, 1999). CAPD is the most common type of PD, and as the name
implies, the patient performs his or her own exchanges, which usually take place every
4-6 hours. CAPD is considered adequate when Kt/V is at least 2.0 (K/DOQI, 2002). In
continuous cycling PD, an automated cycler is used to perform three to five exchanges
over-night while the patient sleeps. A further exchange is performed in the morning after
which the dialysate stays in the abdomen the entire day (called the dwell time).
Nocturnal intermittent PD uses an automated cycler to perform somewhere between six
and eight exchanges over the course of the night with full daytime dwells (i.e., no
daytime exchanges at all) (Gokal & Mallick, 1999). The type of PD a patient receives
depends on several medical factors, such as the amount of residual renal function the
patient has, and the permeability of his/her peritoneum. For example, nocturnal
intermittent PD may be suitable for a patient who has substantial residual renal function
and high peritoneal membrane permeability (Nesrallah, Blake, & Mendelssohn, 2005).
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Neuropsychological Correlates of Dialysis
A number of investigations have established the presence of mild to moderate
neuropsychological dysfunction in the areas of general intelligence, memory and
attention, or processing speed in groups of people with chronic renal failure and
progressive uremia (Hart, 1983; Murawski, 1975; Teschan et al., 1979).
Likewise, neuropsychological functioning after the initiation of dialysis has also
been examined extensively (Gilli & DeBastiani, 1983; Hagberg, 1973; Jackson,
Warrington, Roe & Baker, 1987; McKee et al., 1982; Osberg, Meares, McKee, & Burnett,
1982). Interpretation of many of the early studies is hindered by several methodological
limitations. First, many investigations failed to take into account adequate dialysis
delivery, because standards for minimal dialysis prescription were presented only in
1985 (Gotch & Sargent, 1985). As such, it is difficult to ascertain whether cognitive
deficits obtained in these investigations were an artifact of residual uremia. Second,
comparison across studies examining neuropsychological functioning in HD is hampered
because the timing of neuropsychological testing in relation to dialysis was variable.
That is, some investigators tested subjects just prior to HD, a time when their uremic
state was likely worst, whereas in other studies they were tested at various times after
dialysis (e.g., immediately after, several hours post-HD, 24 hours post-HD). Third, when
examining neuropsychological functioning in areas such as attention and memory, many
investigators failed to account for significant confounding variables such as education
(i.e., failed to match groups for years of education). Lastly, only a few of these studies
considered other potentially relevant demographic factors such as race and age.
Due to the plethora of methodological flaws, many of the early investigations will
not be dealt with directly, but will be mentioned in the context of more recent studies. In
general, neuropsychological investigations of patients on dialysis have examined
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cognitive functioning in the areas of general intelligence, memory, and attention and
processing speed.
Studies Comparing Dialysis Patients to Matched Controls
Wolcott et al. (1988) examined whether dialysis modality may be an independent
factor in predicting the level of functioning of chronic dialysis patients. To that end, they
compared neurocognitive functioning in 17 pairs of CAPD and chronic HD patients
matched for sex, age, education, duration of dialysis and diabetic status. They also
compared the performance of these two dialysis groups to a reference group of agematched controls. At the time of the study, all participants had been receiving dialysis
for at least 6 months. Adequate dialysis was defined as a Kt/V between 0.8 and 1.2 for
patients receiving HD, and four to five two-liter exchanges and regular (i.e., weekly)
monitoring for patients receiving CAPD. The neuropsychological assessment included
measures of attention and processing speed (i.e., number cancellation, Symbol Digit
Modalities, Trail-Making Test- Part A (TMTA)), memory (Rey Auditory Verbal Learning
Test (RAVLT)), and executive functioning (Trail-Making Test- Part B (TMTB)).
The performance of both dialysis groups was mildly impaired across all
measures when compared to the reference group of age-matched controls. Patients
receiving CAPD consistently outperformed those on chronic HD across the majority of
measures. Although this investigation employed relatively rigorous exclusionary criteria,
a serious methodological drawback was that patients receiving HD were tested just prior
to dialysis, a time when their uremic status was likely highest, and their
neuropsychological performance most compromised.
Churchill et al. (1992) conducted a double-blind single-crossover study to
investigate the effect of high-flux HD on neuropsychological functioning. Participants
included a group of stable chronic HD patients who had been on dialysis for at least 3
months and matched controls. Each patient received at least 2 months of conventional
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HD at a Kt/V greater than 1.0. Each patient was then randomly allocated to receive
either conventional or high-flux treatment for 4 months, after which they received the
alternate treatment for 4 months. High-flux HD involves the use of dialysis membranes
with the capacity to remove higher weight molecular substances. The rationale is that if
a greater refinement is achieved in the ability to filter substances, this may lead to fewer
uremic symptoms, and, in this case, improved cognitive functioning. The
neuropsychological battery was chosen to evaluate attention and concentration
(Wechsler Adult Intelligence Scale-Revised (WAIS-R)- Digit Span subtest, Corsi Block
Span, TMTA and the Continuous Performance Test), verbal fluency (Controlled Oral
Word Association and Animal Naming), visuomotor speed (Grooved Pegboard Test and
WAIS-R Digit Symbol Coding), constructional ability (WAIS-R Block Design, Complex
Figure Drawing, and Clock Drawing), memory (Wechsler Memory Scale (WMS)- Logical
Memory and Paired associates subtests, Benton designs and the Recurring Figures
Test) and executive functioning (TMTB, Stroop Test).
For the purposes of the study, none of the 23 neuropsychological variables
showed statistically significant treatment related changes. The performance of both the
conventional and high-flux groups on the selected WAIS-R subtests suggested a lowaverage range of intellectual functioning compared to published norms. For both groups
of dialysis patients other performance deficits, where noted, were most marked on
measures of attention and concentration such as the Continuous Performance Test and
Corsi Block Span, perceptual motor speed (e.g., Digit Symbol Coding) and cognitive
flexibility (e.g., TMTB).
More recently, Pliskin, Yurk, Ho, and Umans (1996) sought to determine whether
well-dialyzed, well-nourished and medically stable end-stage renal disease patients
would exhibit neuropsychological dysfunction compared to demographically matched
medical controls. Their sample comprised 16 well-dialyzed (i.e., MKt/V urea= 1.46)
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patients with end-stage renal disease who had been receiving HD for at least 6 months,
and 12 age-and education-matched controls. All participants demonstrated low-average
intellectual functioning and had an average of 10 years of education. All patients were
tested on a single mid-week, post-dialysis day with a comprehensive neuropsychological
battery that included tests of memory, attention, language, and motor skills.
Findings revealed few significant differences on any of the neuropsychological
domains assessed. Indeed, both groups demonstrated mildly impaired
neuropsychological performance overall. The patients with end-stage renal disease
performed more poorly on two of the three test conditions (i.e., word and color) of the
Stroop Test relative to controls; however, there were no significant differences on other
measures of attention or processing speed.
In a follow-up investigation of attention and mental processing speed, Umans
and Pliskin (1998) administered a battery of six attentional measures (Stroop Test,
TMTA, TMTB, WAIS-R Digit Span Subtest, Paced Auditory Serial Addition Test
(PASAT), Gordon Diagnostic System and the Continuous Performance Test) to 10
stable chronic HD patients (MKt/V= 1.35) and 10 medical controls with normal renal
function. As in their previous investigation, they found that the patients receiving HD
performed more poorly than controls on the Stroop Colour and Word conditions.
Although these differences did not reach statistical significance, they were of a
magnitude that might be of functional importance (i.e., clinically relevant in this patient
population). There were no significant group differences on any other measures. The
authors note that the generalizability of their results is hindered by their relatively small
sample size.
Given the frequent occurrence of vascular disease in patients receiving HD,
Pereira and colleagues hypothesized that the cognitive performance of the patients
receiving HD in their sample would reflect a subcortical pattern of performance. The
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sample included 25 HD patients with Mini Mental State Exam scores greater than 24 and
no history of cerebrovascular disease. The performance of the patients on measures of
verbal list-learning (Wechsler Memory Scale- Third Edition (WMS-III) verbal listlearning), attention and processing speed (Wechsler Adult Intelligence Scale-Third
Edition (WAIS-III) Digit Symbol Coding, TMTA and TMTB), and visual-construction
(WAIS-III- Block Design) were compared to published norms. All HD recipients were
tested an hour into a session of HD (Pereira et al., 2007).
In relation to published normative data, significant deficits for patients receiving
HD were found on the digit symbol coding subtest, the block design subtest, and the
TMTA and TMTB tests, within the context of preserved performances with regard to the
retention and recognition scores from the verbal list-learning task. The authors conclude
that, in accordance with their hypothesis, the pattern of performance is suggestive of
subcortical dysfunction; however, they fail to explicate how their findings are consistent
with such a pattern (Pereira et al., 2007).
Other Relevant Investigations
Griva et al. (2003) examined the neuropsychological functioning of 145 patients
with end-stage renal disease. Their sample consisted of 77 patients receiving HD and
68 receiving PD (CAPD= 45; Automated PD= 23) matched for age and education. All
patients were adequately dialyzed and had been receiving dialysis for at least 6 months
at the time of the study. Both groups completed two neuropsychological assessments
over a 24-hr interval. Patients receiving HD were assessed 2 hr prior to their regularly
scheduled dialysis session (Time 1) and then 24 hrs after the end of their last dialysis
session (Time 2). Patients receiving PD followed the same regimen. Furthermore, each
participant was tested at almost the same time on each testing occasion and alternate
forms of tests were used on second testing sessions. The neuropsychological
assessment consisted of measures of attention and processing speed (i.e., TMTA,
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Symbol Digit Modalities Test), memory (i.e., RAVLT, Benton Visual Retention Test) and
fine motor dexterity (i.e., Grooved Pegboard Test). When averaged over the two timeperiods there were no statistically significant differences on any measures across
dialysis modality. That is, when scores were averaged out, the subjects in both the HD
and the PD groups demonstrated approximately equivalent scores on all the
neuropsychological measures. While the performance of the patients receiving HD was
significantly better at Time 2 than Time 1 on all neuropsychological measures, patients
receiving PD exhibited stable performances across both assessments. An important
finding from the investigation was that absolute levels of cognitive function were
associated with adequacy of dialysis. Specifically, adequacy of dialysis (i.e., Kt/V)
predicted scores on tests of attention and concentration. The major methodological
limitation with the study was the absence of a control group to which the performance of
both dialysis groups could be compared. The failure to find significant cognitive
differences between groups of patients receiving HD versus PD, when patients receiving
HD are tested at the appropriate time (i.e., 24-48 hrs after a session) has been
demonstrated in another recent investigation (Williams, Sklar, Burright, & Donovick,
2004).
Given the literature that demonstrates an association between CKD and anemia,
presumably due to the fact that the kidney produces the vast majority of erythropoietin,
Marsh et al. (1991) studied the effect of rHuEPO (synthetic form of erythropoietin)
treatment on the efficiency of cognitive functioning using neuropsychological measures.
Participants included 24 patients who had all been receiving HD for at least 5 months at
the time of the study. All had some degree of anemia as measured by hematocrit (test
for number of red blood cells) level (M= 23.7). Dialysis was prescribed to achieve a Kt/V
of 1.0-1.2, which was kept constant over the course of the study. The
neuropsychological assessment evaluated attention and processing speed (Symbol Digit
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Modalities Test, TMTB), memory (RAVLT) and verbal fluency (The Controlled Oral Word
Association Test). All participants were administered neuropsychological tests at three
times, first before rHuEPO treatment (Pre-T), after three months of treatment (T3) when
hematocrit values had stabilized at criterion level of 32% or above, and after 12 months
(T12). For each evaluation, subjects were studied on a day following a regularly
scheduled and completed dialysis run as closely as possible to 24-hrs after the
completion of the last dialysis session. Only 14 of the original 24 participants completed
all three neuropsychological testing sessions; however, 19 completed at least two.
Mean scores from the four neuropsychological measures showed improvement
with rHuEPO treatment. After three months of treatment, the Symbol Digit Modalities
Test score increase was significant, while those for the RAVLT and the Controlled Oral
Word Association Test approached statistical significance. After 12 months of treatment,
the TMTB time to completion decreased significantly (i.e., improvement), and the
Symbol Digit Modalities Test showed further improvement, but the RAVLT and
Controlled Oral Word Association Test scores again failed to show significant change.
One has to wonder about the possibility of practice effects as a confounding factor in the
interpretation of results. However, the improvement in the neurocognitive functioning of
individuals receiving HD after the treatment of anemia has been replicated by others
(Grimm et. al., 1990; Lee et al., 2004).
Conclusions
Many of the investigations conducted prior to the 1990s were poorly designed.
The majority failed to consider the adequacy of dialysis delivery. Furthermore, they
failed to consider the timing of test administration in relation to dialysis, failed to account
for anemia in dialysis patients, and neglected to consider demographic variables such as
education and race. Although many of these early investigations found deficits in
neuropsychological functioning in the domains of learning, memory, attention and
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concentration (Gilli & DeBastiani, 1983; Hagberg, 1974; Hart, 1983; McKee etal., 1982;
Teschan et al., 1979; Ryan, Souheaver, & DeWolfe, 1981), the results are
uninterpretable due to the methodological drawbacks. Recent investigations applying
more rigorous methodology appear to suggest at least some evidence for overall mildly
impaired neurocognitive functioning in patients receiving HD compared to controls.
Specifically, several studies suggest compromised functioning in at least some aspects
of attention, and this appears, at the current time, to be the most robust finding across
investigations. This may be attributable to the fact that HD is not a perfect proxy for
transplantation and restores only a fraction of renal function to individuals (i.e., they may
still experience residual uremia). Furthermore, compliance with dialysis regimens is an
ongoing difficulty that is faced by many dialysis clinics (Danovitch, 2005). The few
studies conducted thus far that have examined the cognitive functioning of patients
receiving HD versus PD have found minimal differences, especially when the testing of
individuals receiving HD is conducted at the appropriate time (i.e., not right before
dialysis). There remains a need for well-controlled longitudinal investigations examining
the long-term neuropsychological implications of treatment with either HD or PD.

Section Four- Transplantation and its Neuropsychological Correlates
Transplantation
Transplantation is currently the ideal treatment modality for patients with endstage renal disease, as most patients enjoy an improved quality of life post-renal
transplantation (Fiebiger, Mitterbauer, & Oberbauer, 2004; Lazzaretti, Mulinari, & Rasia,
2004). The major obstacle to this treatment continues to be the shortage of available
organs (Danovitch, 2005; Young & Gaston, 2000). The two types of renal
transplantation are cadaveric (i.e., deceased donor) and living donor. Currently,
cadaveric transplants account for a small majority of kidney transplants, at least in the
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United States. Between 1987 and 2004 cadaveric transplants accounted for more than
half (i.e., 60%) of all kidney transplants, with the remainder being from living donors
(Danovitch, 2005). There are numerous medical criteria that are considered when
selecting potential recipients for transplantation and all recipients are subject to several
screening procedures to determine suitability (e.g., age, psychiatric history, body mass
index). Although there are no strict contraindications to transplantation, the presence of
indicators in any of these domains may further complicate the procedure (Magee, 2005).
The potential recipient also has to be tested for ABO blood type and Human Leukocyte
Antigen tissue typing must be done. The latter involves the important transplant genes
of the Major Histocompatibility Complex. In humans, the Major Histocompatibility
Complex is known as the Human Leukocyte Antigen. It is the compatibility of the genes
of the Major Histocompatibility Complex, between donor (living or dead) and recipient, as
well as blood type compatibility, which dictates, from an immunological perspective,
whether the organ transplantation can be done (Magee, 2005; Suthanthiram & Strom,
1994).
Once transplanted, the recipient's body will recognize the transplanted organ as
foreign and try to destroy it. In immunologic terms, the organ is analogous to the
common cold virus (antigen), which the body will try to destroy. Therefore, transplanted
patients have to be on a lifelong regimen of immunosuppression that typically involves
several agents aimed at different points in the recipient's immune response. Although
this regimen varies across transplant centers, it usually involves the use of a monoclonal
antibody (i.e., thymoglobulin, OKT3) and mycophenolate mofetil in the first 10 days after
transplantation to prevent acute rejection (i.e., destruction of the organ in the first 3 to 6
months post- transplantation). This is followed by a combination of medications that
typically include at least one calcineurin inhibitor (i.e., tacrolimus or cyclosporine), an
antimetabolite (i.e., mycophenolate mofetil) and possibly corticosteroids (i.e.,
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prednisone) (Kirk, Mannon, Swanson, & Hale, 2005). All these agents are used for
various immunological purposes. For example, calcineurin inhibitors, such as
tacrolimus, are typically used for long-term (i.e., maintenance immunosuppression).
Although corticosteroids have historically been a vital element of the posttransplant immunosuppressive regimen, a growing trend in the literature is for patients to
be maintained without corticosteroids post-transplantation (Danovitch, 2005). This is
primarily due to the variety of deleterious effects these drugs have on the human body.
They have been implicated in causing muscular problems, cataract formation, growth
retardation, and body disfiguration and contributing to the development of diabetes
mellitus, arterial hypertension, and metabolic dysregulation (Lerut, 2003).
An important distinction is that between so called steroid-withdrawal, and steroidavoidance protocols. The former involves a tapering of the initial post-transplant
corticosteroid dose over the course of several months, whereas the latter involves
corticosteroid discontinuation after only 3 to 4 days post-transplantation (Prasad, Nash,
McFarlane, & Zaltzman, 2002). As it stands, neither of these protocols is considered for
patients thought to be at high immunologic risk (Hricick, 2005; Vincenti, 2004). The
potential benefits of both these protocols have to be weighed against the associated risk
of graft rejection. Both of these protocols have been associated with higher incidences
of graft rejection, particularly steroid withdrawal (Danovitch, 2005; Pascual, Theruvath,
Kawai, Rubin, & Cosimi, 2002). Evidence indicates that, in general, the use of
corticosteroids in solid organ transplant has not declined substantially over the last 5
years (Hricick, 2005; Kaufman et al., 2004; Vincenti, 2004).
Neuropsychological Correlates of Transplantation
There is a scarcity of investigations examining neuropsychological functioning in
adults post-renal transplantation (Pliskin et al., 2001). Most of the existing literature
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addresses the neuropsychological ramifications of long-term immunosuppression that is
inherent to transplantation; however, this will be discussed in the next section.
Teschan et al. (1979) examined neuropsychological functioning in three groups
of patients in various phases of chronic renal failure. Group 1 (N= 72) consisted of
patients with varying degrees of CKD as indicated by serum creatinine concentrations
that varied from 2 to 29 mg/dl. None of these patients were on dialysis at the time of the
investigation. Patients in Group 2 (N= 77) were all on chronic HD for at least 60 days. It
should be noted that the neuropsychological assessment of these patients was
conducted immediately prior to dialysis. Patients in Group 3 (N=18) were all at least 45
days post-transplant. Finally, data was also obtained from a fourth group of control
participants (N=45). Neuropsychological measures were chosen to assess attention and
memory and included the Trail-Making Test, Auditory Short-term Memory Test,
Continuous Memory Test, Answer Recognition Test, and the Choice Reaction Time
Test.
Across measures, the performance of the transplanted patients was comparable
to the normal control subjects. However, the investigators did not provide data
comparing the performance of the post-transplant patients to either the patients with
CKD, or the dialyzed patients. Furthermore, it is unclear as to how the investigators
assessed adequate dialysis delivery.
Kramer et al. (1996) studied the neuropsychological performance of 15 patients
on chronic HD, who were tested again approximately 15 months after transplantation.
The neuropsychological measures utilized included the TMTA and the Mini Mental State
Exam. Findings indicated a trend towards improvement after transplantation on both the
TMTA and the Mini Mental State Exam; however, this improvement did not reach
statistical significance. The authors acknowledged that their test battery was relatively

Renal Transplant and Cognition 28
circumscribed. Furthermore, it is unclear as to how the investigators controlled for
dialysis related factors such as uremia and adequacy of delivery.
In a recent investigation, Griva et al. (2004) examined neuropsychological
functioning in transplant recipients in relation to normative data and a concurrently
assessed group of pre-transplant patients on dialysis. To that end, they administered
the TMTA, TMTB, Symbol Digit Modalities (written and oral), RAVLT (total recall trials 15, delayed recall), and the Grooved Pegboard Test to 117 transplant patients, and 167
dialysis patients (68 PD; 77 HD). Dialysis dosing was considered adequate if Kt/V met
or exceeded the UK Renal Association Guidelines as follows; for CAPD, a Kt/V of 1.70;
for automated PD (without daytime dwell) a Kt/V of 2.0 and for HD a Kt/V of 1.20. All
patients were tested at approximately the same time of day.
The performance of transplant recipients was significantly better than that of
dialysis patients on the TMTA, Symbol Digit Modalities Test, RAVLT total recall trials 1 -5
and the RAVLT delayed recall, and no worse than that of age-referenced controls (Griva
et al., 2004). The investigators acknowledge that slightly more transplant recipients
scored 1 SD below their age-referenced norms than anticipated in a normal distribution.
The study requires replication utilizing a group of closely matched healthy volunteers.
In one of the most definitive studies to date, Griva et al. (2006) used a
longitudinal design to evaluate neuropsychological functioning before and after renal
transplantation. Twenty-eight medically stable patients were assessed before and again
6 months after renal transplantation using a test battery comprised of tests of attention
and executive function (TMTA, TMTB, Symbol-Digit Modalities Test), memory and
learning (RAVLT, Benton Visual Retention Test), and psychomotor functioning (Grooved
Pegboard Test). All patients were dialyzed adequately prior to transplantation.
Neuropsychological testing during HD was conducted 24-hrs after their last session.
The second testing occurred 6 months after renal transplantation. Results revealed
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significant improvements pre- to post- test on measures of verbal and visual memory
(i.e., RAVLT, BVRT) (Griva et al., 2006). Although there was a trend towards improved
performance on the other cognitive measures none of these differences approached
statistical significance.
Gelb, Shapiro, Hill, & Thornton (2007) examined the neuropsychological
functioning of renal transplant recipients in relation to a group of healthy controls.
Transplant recipients had all maintained a successful graft for at least six months.
Neuropsychological measures included tests of verbal memory (California Verbal
Learning Test- trials 1-5, and 20-minute delayed recall) and attention and executive
functioning (Trail-making test and the Colour-Word Interference Test from the Delis
Kaplan Executive Function System). Results revealed that the healthy controls
outperformed the transplant recipients with regard to the Colour-Word Interference Test
and the California Verbal Learning Test. The authors conclude that the findings suggest
the presence of memory and executive functioning difficulties post-renal transplantation
relative to healthy controls.
Conclusions
There is some evidence to suggest improved neuropsychological functioning
post- renal transplantation. This improvement appears most prominent on tests of
verbal and visual memory, and attention and processing speed. Relative to healthy
controls, there is evidence of ongoing difficulties with aspects of memory and executive
functioning. Replication of these investigations is necessary to confirm the validity of
their findings.

Renal Transplant and Cognition 30
Section Five- Neuropsychological Correlates of Post-Transplant
Immunosuppression
Neuropsychological Correlates of Post-Transplant Immunosuppression
An immunosuppressive regimen is a necessary requirement post-transplantation
to ensure engrafting, as well as to prevent acute and chronic rejection. Given the wide
variety of immunosuppressive medications utilized (mentioned above), and their
differential impacts upon the immune system, it is no surprise that there has been some
interest in the neurocognitive sequelae of exposure to these drugs. Although neurologic
complications due to lifelong immunosuppression, such as frank encephalopathy and
leukoencephalopathy, have been well documented (Benetoli et al., 2004; Christe, 1994;
Cohen & Raps, 1995; Craven, 1991), there is a paucity of literature on the associated
neurocognitive sequelae of such encephalopathy, in relation to immunosuppressive
agents.
DiMartini et al. (1991) conducted a randomized, nonblinded controlled trial of
tacrolimus versus cyclosporine in liver transplant recipients. Cognitive outcome was
assessed via the Mini Mental State Exam, TMTA and TMTB, and the Dementia Rating
Scale. Although there was no significant statistical difference on the Mini Mental State
Exam between the two groups, the researchers found a significantly positive correlation
between plasma levels of cyclosporine and tacrolimus and total time to complete the
TMTB. This study utilized a very small sample size (N=24). Furthermore, the
researchers failed to include an age and education matched control group, and to
equate the two treatment groups for age and education.
More recently, Griva et al. (2004) examined the association between
immunosuppressive medication and neuropsychological outcomes using a sample of
renal transplant recipients. Participants included 117 post-transplant recipients.
Multivariate analysis revealed non-significant group differences on all of the

Renal Transplant and Cognition 31
neuropsychological test scores between the cyclosporine and tacrolimus treated groups
including; TMTA, TMTB, Symbol Digit Modalities Test, RAVLT- (total recall trials 1-5),
and The Grooved Pegboard Test. However, univariate analyses demonstrated that
increasing plasma levels of cyclosporine correlated significantly with poorer
neuropsychological test performance as assessed by the Grooved Pegboard Test,
Symbol Digit Modalities Test-Oral, TMTA, and TMTB. In contrast, serum levels of
tacrolimus were unrelated to the neuropsychological test scores. The researchers
conclude that, although different types of immunosuppressive medication appear to have
comparable effects on neurocognitive performance, increasing serum levels of
cyclosporine appear to be associated with poorer neuropsychological performance,
particularly on measures of fine motor dexterity, processing speed, and executive
functioning.
In an attempt to investigate the relationship between other post-transplant
medications and cognitive functioning, Bermond et al. (2005) examined the memory
functioning of 52 renal transplant recipients in relation to prednisone using the Rey 15Word Test. Results revealed a significant effect for delayed recall on the 15-Word Test
indicating a memory impairment specific to delayed recall in their sample of post-renal
transplant patients receiving prednisone. However, the researchers did not indicate how
they determined the presence of a deficit.
Conclusions
There is some evidence suggesting poorer neuropsychological performance in
post-transplant patients managed on cyclosporine. Modest evidence also suggests a
negative impact of prednisone on delayed declarative memory. Further exploration into
the links between immunosuppression and neuropsychological performance is required.
In contrast to the limited research on the relationship of some immunosuppressants to
cognition (i.e., cyclosporine and tacrolimus), there is an enormous body of literature
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examining the neuropsychological functioning of individuals on corticosteroids. Although
most of this literature exists outside the realm of organ transplantation, many of the
principles established through the study of healthy controls and various other clinical
populations (i.e., rheumatoid arthritis) may be used to predict the potential effects of
corticosteroids in transplant recipients. A review of this literature will now be provided.

Section Six- Corticosteroids and Cognition
The Physiology of Stress
Corticosteroids are released endogenously as a result of the stress response.
Therefore, the basic physiology of the stress response will be reviewed. The concept of
stress as a physiological and neuroendocrine process can be credited primarily to the
work of Hans Selye, an Austrian born endocrinologist. Selye studied the effects of
prolonged stress, such as cold, or injection of poisons, on animals. He observed an
invariable pattern of physical response that he termed the "General Adaptation
Syndrome" that can be broken down into three stages. In the first, or alarm stage, the
initial shock of the stress is followed by a mobilization of forces within the organism to
mitigate against the shock. After a few days of exposure to the stress, the organism
seems to adapt to the stress and its physiology returns to normal (in reality this is just
the immune system working overtime to meet the demands of the stressor). Selye
termed this second stage resistance. Finally, in the last phase termed exhaustion, the
organism's acquired adaptation to the stressful situation is lost, resulting in a series of
physiological changes that may eventuate in death (Marshall & Garakani, 2002). Selye
did not overlook the nervous-neuroendocrine mulithormonal complexity of the stress
response; however, this clarification had to await more detailed biological knowledge
(Angelucci, 2000). He made many important conceptual connections along these lines
that aided in furthering the knowledge about the endocrine substrates of stress. For
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example, he proposed that the adrenal hormones were the final operants of the adaptive
mechanism. He further predicted the anti-inflammatory role of endogenous
adrenocorticotropic hormone (ACTH) and cortisone (Angelucci, 2000).
The endocrine response to stress is complex but involves two main processes.
The primary glands involved include the pituitary and the adrenal glands with the
hypothalamus acting as the moderating factor. In the first pathway termed the
Sympathetic-Adrenal-Medullary axis, or SAM, stressful environmental stimuli cause
direct activation of the adrenal medulla through sympathetic nervous stimulation. This
triggers the adrenal medulla to release the catecholamines epinephrine and
norepinephrine. Approximately ten minutes later there is activation of a second, more
indirect axis termed the Hypothalamic-Pituitary-Adrenal-Cortical system, or HPA, which
causes release of corticotropin releasing factor by the hypothalamus into the blood.
Corticotropin releasing factor stimulates the anterior pituitary to release ACTH, which
travels through the bloodstream to stimulate the adrenal cortex to produce
corticosteroids (i.e., mineralocorticoids, MCs such as aldosterone and glucocorticoids,
GCs such as Cortisol) (Marshall, & Garakani, 2002). Both these axes are closed
systems, with the catecholamines eventually feeding back to various portions of the
sympathetic nervous system to help turn off the SAM axis, while Cortisol eventually feeds
back to the hypothalamus to help shut-off the HPA axis (Angelucci, 2000).
The end-products produced through both these pathways prepare the individual
to cope with stress. However, it is generally thought that the SAM is triggered first and
aids in a rapid response (i.e., prepare for the fight or flight response), while the HPA
allows for a more longstanding response to stress (Marshall & Garakani, 2002; Vedhara,
Hyde, Gilchrist, Tytherleigh, & Plummer, 2000).
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Glucocorticoids and the Brain
The interest in the effects of GCs, such as Cortisol, on cognition was initiated with
the publication of Bruce McEwen's seminal paper "Selective retention of corticosterone
by limbic structure in rat brain" (McEwen, Weiss, & Schwartz, 1968). This paper
demonstrated that the rodent brain was able to recognize hormones, particularly
corticosteroids, the hormones involved in the endocrine response to stress. The
investigators further reported that the brain region showing the highest density of
receptors for corticosteroids was the hippocampus, a brain region significantly involved
in learning and memory. It was with this finding that the stress-hippocampus link was
born. It has been kept alive for the last three decades by a variety of findings confirming
the significant impact of stress hormones (either endogenous or exogenous) on
hippocampal structure and/or function and on animal and human learning and memory
(Lupien & Lepage, 2001; Lupien et al., 1997; Margarinos & McEwen, 1995; Mason,
1968).
The knowledge of the effects of corticosteroids on the brain was furthered with
the discovery of two types of corticosteroid receptors in the rodent brain, a discovery
made by Roussel-Unclaf in the early 1980s (Lupien, et al., 2002a). In humans and
primates, Type I receptors, or mineralocorticoid receptors (MRs), are found primarily in
the limbic system with a preferential distribution in the hippocampus, parahippocampal
gyrus, entorhinal, and insular cortices. They have an affinity for endogenous
corticosteroids six to ten times that of Type II receptors. Type II receptors, or
glucocorticoid receptors (GRs), are found in both subcortical and cortical structures,
including the hippocampus, but have a preferential distribution in the prefrontal cortex
(Lupien & Lepage, 2001; McEwen, Gould, & Sakai, 1992). Many of the studies in the
human literature have examined the impact of exogenous synthetic GCs on cognition
and specifically memory. Some have used dexamethasone, while others have used

Renal Transplant and Cognition 35
prednisone or hydrocortisone. It should be noted that there is variability in the potency
and duration of effect of the various synthetic GCs. This should be kept in mind when
trying to draw comparisons across the various studies in the human literature (Plihal,
Krug, Pietrowsky, Fehm, & Born, 1996).
Memory Terminology
Since much of the research on GCs and cognition has focused on memory, a
brief note concerning terminology relevant to this domain is warranted.
Neuropsychologists have conceptualized memory as a multi-component process, with
taxonomies generally including two types of memory, namely declarative and nondeclarative. The former is the memory for long-term knowledge that can be called to
consciousness and reflected on, alternatively known as explicit memory. The latter is
knowledge that can influence thought and behaviour without necessary conscious
involvement, also termed implicit memory (Squire, 2004). Declarative memory is that
which is referred to when the term "memory" is used in everyday language and is further
broken down into memory for facts (i.e., semantic memory) and events (i.e., episodic
memory). Several lines of evidence with humans have revealed an association between
structures within the medial temporal lobe, and particularly the hippocampus, and
declarative memory (Bayley, & Squire, 2003; Squire, 2004; Tulving, & Markowitsch,
1997). The general classification of medial temporal lobe structures includes those in
the "hippocampus proper," such as the dentate gyrus, Ammon's horn, and the
subiculum, versus the "perihippocampal region" comprising the entorhinal cortex,
perirhinal cortex and the parahippocampal gyrus (Tulving & Markowitsch, 1997).
Memory processing has been broken down into different stages including
encoding (i.e., acquisition), consolidation, and retrieval (Squire, 2004). Memory decay
can occur as a result of the temporal gradient between the stimulus presentation and
recall, or due to interference from information presented before the material to be
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recalled (i.e., proactive interference) or after the material to be recalled (i.e., retroactive
interference) (Squire, 2004). Generally, neuropsychological tests within this domain are
constructed to parse out some of these subcomponents. For example, standardized
neuropsychological verbal list-learning tasks typically comprise a variety of indices. For
example, a comparison of the number of words remembered on the first presentation of
the list (free recall) versus the recognition component may assist in discriminating
encoding from retrieval problems. In fact, the pattern of recall on the first trial itself may
shed light on the relative efficiency of these processes.
Most of the investigations that will be reviewed with regard to GCs and memory
in humans have utilized standardized neuropsychological measures of memory (e.g.,
Newcomer, Craft, Hershey, Askins, & Bardgett, 1994; Wolkowitz et al., 1990), while
others have utilized experimental paradigms (e.g., Lupien et al., 2002b; Lupien, Gillin, &
Hauger, 1999). The latter are more common in the animal literature where investigators
typically rely on spatial memory paradigms, such as the Morris Water Maze (e.g., Luine,
Spencer, & McEwen, 1993; Roozendaal, 2000). Furthermore, with animals,
investigators have attempted to parse out the various subcomponent processes of
memory by controlling the timing of administration of the GC under consideration.
Animal Studies
Several studies have examined the effects of exogenous GCs on various aspects
of learning and memory using animal models. This literature will be reviewed, as some
of the findings are applicable to the human literature.
GRs, and to a lesser degree MRs, in the hippocampus may be lost as a function
of aging. Both hippocampal damage and hippocampal receptor loss is associated with
learning impairments. Several studies have suggested a strong association between
elevated Cortisol levels and hippocampal and/or GR damage (DeKloet, Oitzl, & Joels,
1999; DeLeon et al., 1997; Lupien & LePage, 2001). Sapolsky, Krey, and McEwen
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(1986) argued that, in rats, both elevated levels of GCs, in the short-term as well as
cumulative exposure to normal concentrations of the hormone, lead to hippocampal
degeneration. They observed that rats exposed to daily restraint stress, or given daily
corticosterone (CORT) injections for 21 days, developed atrophy of the apical dendrites
in hippocampal CA3 pyramidal cells. With severe stress, or extended daily
administration of CORT for 12 weeks, the rats developed a permanent depletion in GRs,
resulting from destruction of the host neurons themselves. According to the
"Glucocorticoid Cascade Hypothesis", periods of stress or excessive GC secretion result
in the down-regulation of GRs in hippocampal neurons. A point is eventually reached
where the decreased receptor number desensitizes hippocampal feedback inhibition of
the HPA axis. A hypersecretion of GCs develops as a result of this disrupted feedback
process, which leads to further receptor down-regulation and GC hypersecretion.
Ultimately, there is permanent destruction of hippocampal neurons, at which point the
cycle of destruction is irreversible (Sapolsky et al. 1986). A variety of investigations
using stereological counting techniques in animals have contradicted selective aspects
of the GC cascade hypothesis (Martin, 1990; Vollman-Honsdorf et al. 1997; West, 1993).
Many of the studies assessing GC impacts on brain functioning in animals have
utilized long-term potentiation as an outcome variable. Long-term potentiation is the
long-lasting strengthening of the response of a post-synaptic nerve cell to stimulation
across the synapse that occurs with repeated stimulation, and is thought to be related to
learning and long-term memory (Pease, 2002). In a seminal investigation, Diamond,
Bennett, Fleshner, and Rose (1992) examined the relationship between the magnitude
of hippocampal primed burst potentiation (a low threshold form of long-term potentiation)
and the level of serum CORT using a sample of adrenalectomized (ADX) rats as the
experimental group and adrenal-intact rats as the control group.
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Findings revealed a positive correlation between low levels of serum CORT (i.e.,
1-10 micrograms/dL) and hippocampal primed burst potentiation in the experimental
group that reached a maximum at intermediate levels of CORT (i.e., 11-20
micrograms/dL). High levels of serum CORT were negatively correlated with primed
burst potentiation, thus suggesting an inverted-U relationship between serum CORT and
primed burst potentiation. The finding of an inverted-U-shaped relationship between
serum CORT and long-term potentiation, or primed burst potentiation has been
replicated by other investigators (Pavlides, Watanabe, & McEwen, 1993; Roozendaal,
2000).
Another line of inquiry in the animal literature has examined GC effects on
cognition utilizing spatial memory paradigms. Many forms of mazes (radial maze, Tmaze, Morris water maze) have been used to measure the effects of adrenal steroids on
animal cognition. Luine, Spencer, and McEwen (1993) investigated the effects of
chronic ingestion of CORT (i.e., 8 weeks) on spatial memory performance and
monoamine levels in rats. Twenty 10-month old rats each received one-week of training
on a radial arm maze, followed by 20 trials (two trials/day, morning and afternoon for 2
weeks). After 20 trials on the maze, the rats were divided into two groups. The
experimental group was administered 400 mg/ml of CORT dissolved in ethanol, while
the control group received ethanol in water. Treatment continued for 8 weeks. Spatial
memory was tested and evaluated on an 8-arm maze with a pellet of cat food serving as
reinforcement.
Findings revealed that the overall performance of the CORT treated rats was
unaltered; however, the performance of some of the CORT treated rats was impaired
relative to the control group. The authors conclude that ingestion of CORT for 8 weeks
may impair spatial memory performance in some CORT-treated rats. Other
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investigations have illustrated similar negative effects of CORT on spatial memory in rats
(Dachir, Kadar, Robinzon, & Levy, 1993; Issa et al., 1990).
In a similar vein, the direct effects of GCs on associative learning paradigms, as
defined by various aspects of conditioning behaviours, have also been previously
examined. Passive avoidance learning, acquisition of immobility response, and other
associative learning paradigms consist of having an animal learn the association
between two stimuli (Lupien & McEwen, 1997).
Kovacs, Telegdy, and Lissak (1976) reported that low doses of CORT facilitated
extinction of an avoidance response, while high doses of CORT delayed the rate of
extinction of the conditioned response. This biphasic modulatory effect of GCs has also
been replicated using passive avoidance protocols. In chicks, passive avoidance
learning tasks take advantage of the spontaneous tendency of one-day-old chicks to
peck at small salient objects in their field of view. Normally, chicks presented with a
small bead dipped in a bitter tasting liquid will initially peck at the bead and display an
aversive reaction. They will subsequently avoid a similar, but dry bead for long periods
after the initial presentation. However, if chicks are trained with less bitter tasting
objects, or with diluted concentrations of the aversant (i.e., bitter tasting liquid),
avoidance and hence memory decays in a matter of minutes or hours following training
(Cordero & Sandi, 1998).
Sandi and Rose (1994) used the characteristics of this protocol to determine
whether CORT administration would improve the long-term formation of passive
avoidance learning in chicks. Their results revealed that intra-cerebral injections of
CORT (1 microgram), either 15 min pre-training, or up to 1-hr post-training resulted in a
significantly higher avoidance level in chicks tested at 24-hrs post-training, as compared
to saline injected controls. The researchers concluded that the injections of CORT
facilitated retention of the avoidance response beyond that of saline-injected controls.
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The authors further found an inverted-U dose-response relationship between level of
pre-training CORT and later retention. That is, the lowest and highest doses of CORT
failed to influence avoidance learning, whereas the medium dose (i.e., 1 microgram)
facilitated retention at 24-hrs post-training.
In a follow-up investigation, Sandi and Rose (1997) examined two further
phenomena using chicks. First, they examined the effects of different concentrations
(i.e., 10% and 100%) of the abovementioned aversant, on long-term memory, and
plasma CORT levels. Second, they examined the effects of injecting different CORT
doses (i.e., 0.1,1, and 5 micrograms/chick) into an area of the hypothalamus called the
intermediate medial hyperstriatum ventrale on memory acquisition and consolidation.
Doses were administered in the post-training period (5 min), and the effects on the
establishment of a long-term memory (as evaluated 24-hrs post-training) in chicks
trained either with a 10% aversant, or a 100% aversant were evaluated.
Results revealed that only chicks trained on the strong aversant task (100%), a
learning situation that results in a high percentage of chicks forming long-term
memories, experienced an increased release of CORT because of training. Chicks
trained in the weak aversant task (10%), which leads to retention of the avoidance
response for only a few hours (i.e., <9 hrs), showed circulating CORT values
comparable to untrained chicks. With regard to the second objective, results indicated a
dose-dependent effect of CORT on long-term memory expression, as evaluated 24-hrs
post-training. Intracerebral administration of 1 microgram of CORT facilitated long-term
memory expression in the chicks trained with the weak task (10% aversant); however, a
higher dose of 5 micrograms failed to produce this effect. Additional doses of 1 and 5
micrograms of CORT impaired long-term memory in the chicks trained with the strong
task (100%) aversant (Sandi & Rose, 1997).
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The authors draw several conclusions from these two investigations. First, a low
central corticosteroid action appears detrimental to memory formation as training chicks
in the 10% aversant condition did not produce any change in circulating CORT levels
and resulted only in transient memory. Second, a moderate central corticosteroid action
appears to facilitate the establishment of enduring memory. This conclusion was based
on the observation that the chicks trained with the 100% aversant had increased
circulating levels of CORT and also a long-term memory of the event and chicks trained
with the 10% aversant and then given exogenous CORT also exhibited increased longterm memories for the event. Third, the authors conclude that excess CORT appears to
be detrimental for the mechanisms of long-term memory formation since there was
reduced retention in strongly aversant trained chicks (100%) additionally injected with 1
or 5 micrograms of CORT (Sandi & Rose, 1997).
The authors speculate that the contrasting memory abilities of chicks trained with
the 10% or 100% aversant may be related to a differential manipulation of MR and GR
receptors. Indeed, many of the results in the animal literature implicate involvement of
MR and GR corticosteroid receptors in moderating the effects of corticosteroids on
cognition, and particularly memory (Diamond et al. 1992; Kovacs, 1976; Lupien &
McEwen, 1997; Sandi & Rose, 1997).
The first study to systematically manipulate MR and GR receptors, with the hope
of further elucidating their relative contributions to memory acquisition and consolidation
was conducted by Oitzl and DeKloet (1992). In this investigation, separate groups of
adrenal intact rats were administered either MR or GR antagonists. Antagonist
administration was given either before training the animal in the Morris water maze for
the first time (pre-training/session 1), after training the animal in the Morris water maze
for the first time (post-training/session 1), or before being measured on the Morris water
maze for the second time (pre-session 2). In this manner, it was possible to measure
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the effects of corticosteroid antagonists on the acquisition (i.e., pre-training/session 1)
and consolidation (i.e., post-training/session 1) processes of memory. Finally, injecting
the corticosteroid antagonists into another group of rats that had already learned
(acquired and consolidated) the maze on a first occasion (pre-session 2), allowed the
researchers to measure the effects of corticosteroid antagonists on the retrieval process.
The administration of the GR antagonist impaired the performance of the rats
that were injected before and after their first session in the water maze. However, it did
not affect the performance of rats that were injected before performing the maze for the
second time (Oitzl & DeKloet, 1992). That is, when the animal was acquiring and/or
consolidating the task, GR antagonist administration had a detrimental effect on their
performance. However, once the animal had acquired and consolidated the task, GR
antagonist administration no longer had an effect on performance. The authors
conclude that GR receptors are involved in the process of memory consolidation.
On the other hand, the administration of the MR antagonist had no effect on the
performance of the rats that were injected before and after their initial session in the
water maze. Furthermore, it did not impair the performance of the rats that were injected
before performing the maze on the second occasion. The authors were unable to
elucidate a specific role of MR receptors in the process of memory formation based on
these results. However, a subsequent investigation led the authors to suggest that MR
receptors may be involved in the process of evaluating a situation and selecting an
appropriate response (i.e., sensory integration) (DeKloet, Oitzl, & Joels, 1993).
Other investigators have replicated the results of this study. Sandi and Rose
(1994) examined the effect of specific MR and GR antagonists on long-term retention of
a passive avoidance-learning paradigm. They found that injection of the MR antagonist
with CORT did not significantly alter retention of the avoidance response. The opposite
was true when the GR antagonist was dovetailed with CORT administration (i.e.,
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significant impairment of retention of the avoidance response). The authors concluded
that MRs alter the chicks' reactivity to non-specific aspects of training (i.e., interpretation
of environmental stimuli and selection of a behavioural response). Meanwhile, GRs
appear to be involved in memory consolidation.
Recently, Conrad and collaborators investigated the effect of MR and GR
agonists administered at three points in time (120 min prior to learning (i.e., Trial 1),
immediately after Trial 1, or 120 min after Trial 1) on adrenalectomized (ADX) rats'
performance on the Y-maze (Conrad, Lupien, Thanasoulis, & McEwen, 1997). Their
design comprised four groups, including two groups of ADX rats administered an MR or
GR agonist, an adrenal intact SHAM group administered a sesame vehicle, and an ADX
group administered a sesame vehicle. The Y-maze is a two-trial recognition memory
test that taps into the innate tendency of rats to explore new (i.e., never before
encountered) environments.
Results revealed that the ADX rats treated with the MR agonist performed as
well as the SHAM-treated rats with regard to spatial recognition memory. However, the
ADX rats treated with the GR agonist performed as poorly as the ADX rats treated with
the sesame vehicle. However, both experimental groups explored the Y-maze more
than controls (ADX and SHAM) over the course of the entire experiment (prior to trial 1,
immediately after trial 1, 120 min after trial 1) (Conrad, Lupien, Thanasoulis, & McEwen,
1997).
The authors suggest that the findings indicate a discrepancy in the proficient use
of exploratory behaviour by the two experimental groups. Whereas, the rats treated with
the MR agonist used inspective behaviour to acquire and/or consolidate spatial
information, the increase in exploratory behaviour of the rats administered the GR
agonist did not produce improved spatial recognition memory (recall that these are ADX
rats, and hence there was no MR occupancy at the time of GR agonist administration).
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Conclusions from animal investigations
Several tentative conclusions can be drawn about the effects of acute
administration of GCs on cognition based upon the animal literature. First, there
appears to be a preponderance of evidence implicating a dose-dependent relationship
between level of serum corticosteroid and electrophysiological, and cognitive (i.e.,
spatial paradigms, passive-avoidance protocols) measures of brain function. This
relationship most likely resembles an inverted-U shape with long-term potentiation and
cognitive performance at their best with moderate exogenous levels of GCs. Second,
the relationship between GC exposure and cognition appears to be dependent on the
relative activation of the MRs and GRs. While MRs appear important for arousal and
orientation to the environment, GRs appear more central to the process of memory
consolidation. Third, the facilitational action of GRs appears dependent on the
occupation of MRs. That is, when MRs are completely unoccupied, activation of GRs
will not facilitate memory consolidation. Conversely, when both receptors are highly
occupied, GRs have an inhibitory action on memory consolidation. Fourth,
administration of selective MR or GR agonists or antagonists appears to be the definitive
manner in which to study their relative contributions to various cognitive processes.
The remainder of this paper will focus upon the investigations that have
examined the effects of GCs on human cognition. In contrast to the investigations using
animals, the majority of these studies have utilized cognitive and neuropsychological
tests as their primary outcome measures. Furthermore, the vast majority, have
examined cognitive functioning in the context of acute supraphysiological doses of
exogenous GCs. To date, there is a paucity of information regarding the long-term (i.e.,
one to two year) effects of therapeutic doses of exogenous GCs on cognitive functioning
(Belanoff, Gross, Yager, & Schatzberg, 2001; Lupien & McEwen, 1997; Lupien &
LePage, 2001; DeKloet, et al. 1999).
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Investigations in Human Populations
Endogenous Glucocorticoids
A variety of studies have examined neuropsychological functioning in patients
exposed, for various reasons (i.e., Cushing's Syndrome, Post-Traumatic Stress
Disorder), to chronically elevated levels of endogenous GCs. Evidence has suggested
that the effects of elevated endogenous GCs on neuropsychological functioning may be
somewhat different from that of exogenous GC administration (Lupien et al., 2002a;
Schmidt et al., 1999; Young, Sahakian, Robbins, & Cowen, 1999). A primary reason for
this discrepancy may be the differential binding of MRs and GRs by endogenous versus
exogenous GCs. CORT and Cortisol bind preferentially to MRs, while synthetic GCs
such as dexamethasone and prednisone have much higher affinities for GRs (Plihal,
Krug, Pietrowsky, Fehm, & Born, 1996; Schmidt et al. 1999). Other reasons include
differences in the time course and level of hypercortisolemia, and the presence or
absence of related biochemical changes (i.e., alterations in levels of corticotropin
releasing factor and ACTH) (Keller-Wood & Dallman, 1984). However, it appears
reasonable to suggest that different individuals exposed to similar substances (i.e.,
Cortisol and synthetic Cortisol like substances) via somewhat different pathophysiological
mechanisms, may display some similar cognitive characteristics. Therefore, a review of
some of the germane literature with regard to one of the well-researched states of
elevated endogenous hypercortisolemia (i.e., Cushing's Syndrome) will be provided.
Cushing's Syndrome
Cushing's Syndrome is an endocrine disorder characterized by an
overproduction of steroid hormones, mainly Cortisol, from the adrenal cortex (Martignoni
et al., 1992). The syndrome is divided into an ACTH-dependent and an ACTHindependent subtype. The former comprises the condition resulting from pituitary ACTH
overproduction, termed Cushing's disease. The latter is comprised of conditions
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involving adrenal tumours (adenoma or carcinoma), or states in which excessive
treatment with GCs has resulted in Cushing's Syndrome (Belanoff et al., 2001; Starkman
etal., 1992).
Martignoni et al. (1992) examined neuropsychological functioning in 24 untreated
patients diagnosed with Cushing's disease, all of whom presented with the condition for
at least 1 year, compared to healthy controls. The investigators state that patients
identified as having affective disturbances, psychosis, and confusional states were
excluded; however, they do not report on measures utilized for determining exclusion.
Patients were administered a standard neuropsychological battery that included tests of
attention, memory, language, and visual-spatial abilities.
Findings indicated significant group differences on the Logical Memory and
Visual Reproduction subtests of the WMS (both short and long delayed recall), and Digit
Span backwards. In all cases, the performance of the patients with Cushing's disease
was impaired relative to the control group.
Starkman, Gebarski, Berent, and Schteingart (1992) examined the relationship
between hippocampal formation volume, memory dysfunction, and Cortisol levels in 12
patients with Cushing's syndrome. They found that patients with Cushing's syndrome
exhibited impaired performance relative to normal controls on both immediate and
delayed (i.e., 30 minutes) verbal recall on the Logical Memory subtest of the (WMS).
Interestingly, the researchers found a significant positive correlation between
hippocampal formation volume and scores on tests of verbal learning and memory.
Significant limitations to this study were the inclusion of subjects with both subtypes of
the syndrome (i.e., sample comprised both ACTH-dependent and independent
individuals) and the relatively small sample size.
More recently, Starkman, Giordani, Berent, Schork, and Schteingart (2001)
examined neuropsychological functioning in 48 patients with untreated Cushing's
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disease, relative to 38 healthy controls. Neuropsychological measures included several
subtests of the WAIS-R, and the Mental Control, Visual Memory Span, Logical memory,
Paired Associate Learning and Visual Reproduction subtests of the WMS. The subtests
from the WMS were grouped into a composite memory score.
Patients with Cushing's disease performed significantly worse than controls on all
three neuropsychological domains (i.e., WAIS-R Verbal and Performance IQ, and the
WMS Memory composite). Post-hoc analyses revealed that the performance of the
group with Cushing's disease was significantly lower than that of controls on four of the
five verbal subtests of the WAIS-R (Comprehension, Vocabulary, Similarities, and
Arithmetic). However, the only WAIS-R Performance subtest that differentiated the
groups was Block Design, with the patients with Cushing's disease scoring significantly
lower than controls. Patients with Cushing's disease performed significantly worse than
controls on both measures of verbal memory from the WMS (i.e., Logical Memory and
Paired Associate Learning), for both immediate and delayed recall trials. There were no
significant differences between the groups on any of the other WMS subtests.
Starkman, Giordani, Gebarski, and Schteingart (2003) investigated whether the
increase in the hippocampal formation volume of patients with Cushing's disease treated
with a drug that lowered Cortisol concentrations to normal levels would be associated
with improvements in neurocognition. Neuropsychological testing included tests of
verbal cognition, learning, and memory. After partialling out age, education, duration of
illness, and time since surgical treatment, greater improvement in word list-learning was
associated with a greater increase in hippocampal formation volume.
In a similar vein, Hook and colleagues sought to better understand whether the
negative effects of Cortisol on cognition in patients with Cushing's disease can be
reversed and, if so, how long after successful treatment this recovery might begin.
Participants included 72 patients with Cushing's disease, ranging in age from 18 to 72

Renal Transplant and Cognition 48
years, tested at 3-5 months, 6-12 months, and 13-18 months, after successful surgical
treatment. At all assessment periods Cortisol samples were collected, and patients were
administered a neuropsychological battery comprised of tests of verbal list-learning,
verbal fluency, attention, and personality. In order to better examine the effects of age
on the independent variables the sample was divided into "younger" and "older"
subgroups. Participants in the younger subgroup ranged in age from 18-39 years, while
those in the older subgroup ranged from 40-72 years (Hook et al., 2007).
Findings revealed a specific pattern of recovery post-surgery with significant
recovery of verbal memory and fluency, but not brief attention. With regard to the
question of age, participants in the younger subgroup exhibited a tendency to rebound
more quickly on select cognitive tests post-surgery (verbal list-learning) relative to
participants in the older subgroup. Finally, the improvement in verbal recall was
associated with the increase in hippocampal formation volume one year after treatment
(Hook et al., 2007).
Conclusions
Overall, the findings with regard to neuropsychological functioning in untreated
Cushing's syndrome have suggested that individuals exhibit impairments on tests of
declarative memory. Additionally, there is some evidence of impairments on tests
measuring aspects of executive functioning; however, these findings have not been as
consistent. Modest evidence suggests that there may be a reduction of hippocampal
formation volume in long-standing untreated Cushing's syndrome that is associated with
impairments in verbal learning and memory. An improvement in verbal memory and
verbal fluency has been demonstrated after treatment of Cushing's disease. The
improvement in verbal memory has been associated with the increase in hippocampal
formation volume after the treatment of Cushing's disease. The rate of recovery may be
faster for younger (18-40) versus older (45-70) patients with Cushing's disease.
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Normal Aging
Several studies have explored basal Cortisol changes as a function of advancing
age, with equivocal results. Cross-sectional studies have generally reported that basal
Cortisol levels do not change across the age-span in healthy subjects (Carvalhaes-Neto,
Ramos, Vieira, & Kater, 2002; Waltman, Blackman, Chrousos, Riemann, & Harman,
1991). However, the results of within-subjects designs contradict these findings. For
example, Deuschle et al. (1997) examined the diurnal and pulsatile features of the HPA
system in 11 healthy females and 22 healthy males ranging in age from 25-85. All
subjects underwent 24-hr blood sampling with 30-min sampling intervals. However, from
18.00 to 24.00 hrs, blood was sampled every 10 minutes for analysis of pulsatile
features of HPA activity.
Results indicated a significant age-associated increase in mean plasma Cortisol
concentrations. Although there was no age-cortisol correlation during daytime, there
was a strong impact of Cortisol plasma levels in the evening (Deuschle et al., 1997). The
researchers conclude that their results provide evidence for increased basal activity and
flattened diurnal amplitude of the HPA system in the elderly.
Lupien et al. (1996) examined Cortisol levels and neuropsychological
performance in a group of 51 healthy elderly subjects (ages 60-90) over a 3 to 6 year
period. Once per year, basal Cortisol levels were examined using hourly sampling over a
24-hr period. Three Cortisol measures were computed for each subject. These included
the 24-hour averaged level (24-hr avg.), the Cortisol slope, and the last 24-hour (last)
measurement. The investigators performed a literature review when deciding what
plasma Cortisol level would constitute hypersecretion in aging, arriving at the value of
12.5 micrograms/ml/hr. Applying these three endocrine measures to their sample, they
discovered the presence of three subtypes of elderly. The first group termed the
Positive Slope Elevated Group, or PSE, demonstrated a positive Cortisol slope and
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elevated levels of both 24-hr avg. and last measures. This group comprised an
estimated 23.5% of the population. The second and largest group termed Positive Slope
Moderate, or PSM, comprised individuals with a positive Cortisol slope, but below criteria
(i.e., 12.5 mcg/ml/hr) levels of both 24-hr avg. and last measures. This group comprised
an estimated 56.8% of the population. Finally, the third group termed Negative Slope, or
NS, demonstrated both a negative Cortisol slope and below criteria levels of 24-hr avg.
and last measures. This group comprised an estimated 19.6% of the population.
Interestingly, the researchers were able to externally validate their typology using
a battery that included experimental neuropsychological measures in the domains of
memory (both immediate and delayed recall), attention (selective and divided), and
language (verbal fluency and figural naming) (Lupien et al., 1996). The individuals in the
PSE group exhibited impaired performance on selective attention and declarative
memory tasks relative to individuals in the PSM and NS groups. The individuals in the
PSM group demonstrated normal memory but deficits in vigilance relative to the other
two groups. Finally, individuals in the NS group exhibited performance comparable to
young healthy controls on all of the neuropsychological measures.
Lupien and colleagues have subsequently replicated their findings with regard to
memory functioning in these three groups. Furthermore, they were able to show that the
total hippocampal volume of the PSE group was significantly reduced by 14% relative to
the other two groups (i.e., PSM and NS) (Lupien et al., 1998).
Seeman, McEwen, Singer, Albert, and Rowe (1997) used data from a
community-based longitudinal study of older men and women, aged 70-79 years, to test
the hypothesis that exposure to increasing levels of Cortisol is associated with declines in
memory. Neuropsychological measures included WMS Logical Memory (immediate and
delayed recall) and the Boston Naming Test. Results indicated an association between
greater Cortisol excretion and poorer baseline memory performance in women.
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Furthermore, women who exhibited increases in Cortisol excretion over a 2.5- year
follow-up period were more likely to show declines in memory performance. No such
findings were produced for the men in their sample.
More recently, MacLullich et al. (2005) examined the hypothesis that higher
plasma Cortisol levels and altered sensitivity to GCs are associated with worse cognition
and greater brain atrophy using a sample of healthy elderly males between 65 and 70
years of age. All subjects had plasma Cortisol measured at 09:00 and 14:30 hrs of the
same day. Furthermore, sensitivity to dexamethasone was assessed with a low dose
dexamethasone suppression test during which 0.25 mg of dexamethasone was taken at
23:00 hrs and blood was drawn at 09:00 hrs the following morning. Cognitive testing
included: Raven's Progressive Matrices (number correct in 20 minutes), WMS- Logical
Memory (immediate and delayed recall) and Visual Reproduction, RAVLT, Controlled
Oral Word Association Test and the National Adult Reading Test. Finally, all subjects
underwent brain imaging via magnetic resonance imaging. Data reduction for cognitive
test scores using principal components analysis was performed. The first unrotated
component accounted for 5 1 % of the variance in cognitive function, and was labelled the
General Cognitive Factor.
Cortisol levels at 09:00 hrs correlated negatively and significantly with the
general cognitive factor and Logical Memory 24-hr delayed. There was no significant
correlation between hippocampal volume and Cortisol level; however, the authors
suggest that their use of a cross-sectional design may have limited their ability to find
such an effect. Interestingly, although the investigators did not find a consistent
relationship between Cortisol levels and brain volumes, they did find a significant
relationship (i.e., negative correlation) between 14:30 hr Cortisol levels and left temporal
lobe volume. Others have reported similar left-side worse laterality findings with
elevated Cortisol (Hull, 2002; van der Beek, et al., 2004).
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Following the evidence of an association between increasing plasma Cortisol and
greater impairments of declarative memory, Li et al. (2006) explored the association
between salivary Cortisol and cognitive changes in cognitively intact older (mean age
was 63 years) people in a 3-year longitudinal study. Cortisol samples were collected at
home at 08:00,15:00, and 23:00 hrs 2-3 days prior to the administration of
neuropsychological tests annually for 3 years. Cognitive measures included tests of
global cognition (Mini Mental State Exam), verbal memory (WMS-III Logical Memory),
visual memory (delayed object recall), attention and concentration (Stroop test, TMTA
and TMTB), and language (Boston Naming Test).
Findings revealed a significant association between Cortisol levels at all three
sampling points and poorer performance on tasks of declarative memory and executive
functioning. Of the 46 participants who completed the entire 3-year study, higher initial
Cortisol concentration at 23:00 hrs predicted a decline in performance on the delayed
recall component of the WMS-III logical memory subtest. Importantly, the study
extended the findings of Lupien et al. (1998) in demonstrating that the subgroup of
subjects with increasing Cortisol concentrations over time (positive Cortisol slope)
consistently had the poorest verbal recall scores at the beginning, middle, and end of the
study. Finally, analyses revealed a significant association between higher mean Cortisol
levels and poorer performance on the TMTB and the Stroop test. The authors suggest
this finding is indicative of an influence of Cortisol on structures in the prefrontal cortex.
In accordance with the evidence of a high concentration of corticosteroid
receptors in the prefrontal cortex, McCormick, Lewis, Somley and Kahan (2007)
examined the association between salivary Cortisol levels and performance on the
Wisconsin Card Sorting Test (WCST). Their sample included 120 undergraduate
students between the ages of 17 and 22. Each participant was tested individually within
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18:00 and 22:15 hrs, and saliva samples were collected before and after the completion
of cognitive testing.
Results suggested a positive association between the first (arrival) sample of
Cortisol and perseverative errors on the WCST for women and a negative association
between these values for men. The authors state that, for women, the finding is in
accordance with the literature that reports a negative association between Cortisol levels
and working memory (Young, Sahakian, Robbins, & Cowen, 1999), while for men it is
consistent with prior research that demonstrates a U-shaped relationship between
Cortisol levels and working memory (Lupien, Gillin, & Hauger, 1999). It should be noted
that the mean arrival Cortisol level for men in their sample was less than the value for
women.
Conclusions
Based on the abovementioned studies, it is important to consider various
methods of measurement when quantifying Cortisol due to the temporal variability of this
hormone. Second, an increase in the basal concentration of Cortisol with aging may not
be a universal phenomenon; rather, there may be subtypes of elderly individuals. Third,
there is some evidence for impaired declarative memory and some aspects of attention
in those individuals exposed to chronic endogenous hypercortisolemia (e.g., PSE
group). Fourth, modest evidence suggests that there is an association between
endogenous Cortisol and executive functioning, and this relationship may vary by
gender. Finally, there appears to be some evidence for a relationship between
decreased hippocampal volume with chronic exposure to elevated endogenous Cortisol.
Experimental Studies in Healthy Human Subjects
The effects of exogenous GCs on cognitive functioning in healthy individuals
have also been examined. Wolkowitz et al. (1990) investigated the memory
performance of 11 medically healthy, medication and caffeine free volunteers on a list-
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learning task. All participants were screened for significant psychiatric conditions.
Prednisone administration was carried out (80 mg daily for 5 days) in a double-blinded
manner. Memory testing was conducted once during the initial 5-day placebo period,
once after 4 days of prednisone administration, and once again 7 days after
discontinuation of the prednisone. Findings indicated that prednisone was associated
with a significantly higher rate of errors of commission (i.e., incorrectly identifying
distractors as target words) than was placebo during the test of recognition memory.
There were no significant effects of prednisone on measures of attention, or free recall.
The first author has replicated these findings in a subsequent investigation (Wolkowitz,
1994).
Newcomer, Craft, Hershey, Askins and Bardgett (1994) examined the effects of
4-day administration of dexamethasone treatment on cognitive functioning in healthy
adults. Cognitive testing was performed at 16:00 hrs before, during, and after a 4-day
period of double-blinded, placebo-controlled treatment with dexamethasone. Subjects
were administered dexamethasone at 23:00 hrs for four consecutive days (0.5, 1,1,1
mg, respectively). Cognitive measures included the logical memory subtest from the
Wechsler Memory Scale-Revised (WMS-R), a serial addition task during which
participants were asked to calculate the sum of a series of presented numbers, and the
Benton Judgement of Line Orientation Test, a task in which participants are shown a line
and must select the line it most closely matches in orientation from a presented array.
Results indicated significantly lower logical memory recall scores for the
experimental group as compared to matched controls, but only after the fourth day of
treatment with dexamethasone (Newcomer et al., 1994). The effect was apparent on
both immediate and long delayed recall. While the performance of the control group on
logical memory recall improved over the four treatment days (practice effect) that of the
experimental group declined. There were no significant group differences on any of the
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other cognitive measures. The finding that the experimental group made errors of
omission but not commission on the paragraph recall task is in direct contrast to the
Wolkowitz et al. (1990) investigation. The authors suggest that the discrepancy may be
explained by the use of two different memory measures and the younger sample of
participants in their study. Alternatively, the use of two different synthetic GCs may
account for this discrepancy. The selective impairment of immediate and delayed recall
on prose memory tasks has been replicated by other investigators (Brunner, et al., 2005;
DeQuiervain, Roozendaal, Nitsch, McGaugh, & Hock, 2000; Newcomer et al., 1999).
DeKloet (1993) points out that the rendering of statements regarding the effects
of exogenous GCs on cognitive functioning in humans has been hampered by the
methodological limitations of many of the studies thus far conducted. He points out that
in the animal literature there has been an attempt to conduct investigations that allow for
the differential manipulation of steroid receptors through use of agonists, antagonists, or
hormone replacement protocols. This type of design has thus far been lacking in the
human literature. Furthermore, few studies in the human literature have considered the
circadian variation in endogenous Cortisol levels when examining the effects of
exogenous doses of GCs on cognition.
A recent pair of investigations by Lupien and colleagues (Lupien et al., 2002a,
2002b), were conducted to address some of these relevant issues. In the first study,
(Lupien et al., 2002a) the experimenters used a hormone replacement procedure in a
double-blinded placebo controlled protocol. They pharmacologically decreased Cortisol
levels by administration of metyrapone (a potent inhibitor of Cortisol synthesis), and then,
in the second study, restored baseline Cortisol levels by subsequent hydrocortisone
replacement therapy. Memory function, using a 12-word list presented over three trials,
was assessed after each pharmacological manipulation. Both immediate and delayed
(i.e., 20 min) recall was measured. Four different lists of words were used to rule out
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practice effects. Treatment with metyrapone significantly impaired delayed recall in the
experimental group relative to the placebo group, suggesting that metyrapone
administration had a negative impact on the retrieval component of memory.
In the second investigation (Lupien et al., 2002b), researchers utilized the natural
circadian fluctuation of Cortisol, and tested the effect of a bolus injection of 35 mg of
hydrocortisone on memory. Hydrocortisone was administered in the late afternoon, a
time thought to coincide with a very low level of endogenous Cortisol circulation. The
dependent variable utilized was an incidental encoding task that required shallow and
deep levels of processing. For the shallow encoding condition, subjects were asked to
answer if the word presented to them contained the letter "T". These words were
presented once and subjects had to answer "yes" or "no" using a keypad. Deep
encoding required the subject to decide if the words presented to them contained more
than one homonym. During recognition testing, 30 word stems were presented
randomly to subjects. Each word stem comprised the first three letters of a word and the
participant was required to indicate whether the presented word stem was part of a word
previously presented or not.
Although there were no significant group differences on the word stem
recognition task, there was a significant main effect of depth of processing. Shallowly
encoded words consistently lead to lower recognition performances, when compared to
deeply encoded words. Perhaps more notable was the finding that the treatment group
responded significantly faster for all correct trials when compared to the placebo group
(Lupien etal., 2002b).
Taken together, the results of these studies demonstrate that GCs can modulate
human memory functioning, possibly via differential activation of MRs and GRs. The
administration of metyrapone in the first investigation (Lupien et al., 2002a) likely
resulted in a decreased production of Cortisol, reduced MR occupancy with relatively
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little GR occupancy, and, hence, deficient delayed memory. With regard to the second
investigation, hydrocortisone injection in the afternoon (circadian trough, and a time
when only MRs would have been occupied by the endogenous Cortisol) may have led to
partial activation of GRs. This may have resulted in increased cognitive efficiency in the
group receiving hydrocortisone, relative to placebo (Lupien et al., 2002b).
Although there are several investigations highlighting the effects of exogenous
GC administration on memory, other cognitive domains such as executive functioning
have been implicated with less consistency. Executive functions have generally been
operationalized as higher order control processes that integrate cognitive abilities, and
that are primarily attributed to the frontal lobes (Baddeley & Delia Sala, 1996).
Specifically, they are thought to involve elements of response inhibition, self-regulation,
planning, problem solving, cognitive set-shifting, and working memory (Reitan &
Wolfson, 1994; Stuss & Benson, 1986). Working memory involves the process of
holding information in storage temporarily, while simultaneously working on other
cognitive tasks (Miyake et al., 2000). A good example would be trying to remember a
string of digits, wherein one must keep the previously presented digits in mind while
trying to encode new digits. Executive functions subsume a number of different
cognitive operations and the term "executive functions" has been used interchangeably
in the literature with such terms as "executive processes", "higher-order abilities" and
"complex attention" (Burgess, 1997). The term "complex attention" will be used to make
reference to executive functions in the remainder of this paper. This is because the
majority of the research presented here did not use measures of problem solving or
concept formation, skills traditionally measured in studies of executive functioning (Stuss
& Benson, 1986).
Young et al. (1999) examined the effects of hydrocortisone administration on
learning, memory, and executive functioning. Subjects included 20 healthy male
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volunteers with no history of a medical or psychiatric disorder. Subjects were
administered hydrocortisone (20 mg twice daily) for 10 days in a randomized, placebo
controlled, within-subjects crossover design. Neuropsychological measures included
selected subtests of the Cambridge Neuropsychological Test Automated Battery
including spatial working memory, paired associates learning, pattern and spatial
recognition and the Tower of London test. Chronic (i.e., 10 day) administration of
hydrocortisone was associated with more errors on both the spatial working memory and
paired associates subtests of the Cambridge Neuropsychological Test Automated
Battery. The authors conclude that the pattern of deficits produced by hydrocortisone
administration is more consistent with frontal than hippocampal deficits.
Lupien, Gillin, and Hauger (1999) examined the effects of various doses of
hydrocortisone on tasks assessing working memory and declarative memory in four
groups of 10 healthy young men. During infusion, subjects were administered an itemrecognition working memory task, a paired-associate declarative memory task, and a
continuous performance task used to control for steroid effects on vigilance. They found
significant acute effects of the highest dose of hydrocortisone on working memory
without any significant effect on declarative memory. The authors conclude that working
memory may be more sensitive than declarative memory to acute increases in GC
levels.
It makes intuitive sense that deficits of particular aspects of complex attention
would result after exogenous GC administration. Most exogenous GCs (i.e.,
hydrocortisone, prednisone) bind with great affinity to GRs that are distributed widely
throughout the brain, but preferentially in the prefrontal cortex. Indeed, further
investigation is required to substantiate the abovementioned findings with regard to
deficits of complex attention, and to explore the exact nature of these deficits (Belanoff
et al., 2001; Brunner et al., 2005; Sapolsky, 2000).
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Conclusions
Acute administration of GCs to healthy controls negatively impacts declarative
memory. This has been demonstrated using both paragraph recall and verbal listlearning tasks. There is also modest evidence to suggest impairments in some aspects
of executive functioning within young adult (i.e., between 30 and 45 years old) subjects
exposed acutely to high doses of GCs. The majority of investigations have failed to
consider the circadian fluctuation of Cortisol when drawing conclusions about exogenous
GC administration. Furthermore, few studies have used GC agonists or antagonists to
evaluate GC effects on cognition.
Glucocorticoid Therapy
GCs are used therapeutically for their anti-inflammatory and immunosuppressive
properties to treat various conditions such as rheumatoid arthritis, and various
autoimmune diseases. Despite this fact, there are few investigations examining GC
action in patient groups treated for various conditions. This is likely due to the many
confounding factors that would undoubtedly accompany such a design. However, such
investigations are required to address the impacts of GCs on cognition in people for
whom it may be a daily concern. A review of the most relevant work in this area is
provided.
Rome and Braceland (1952) evaluated over 100 patients who were being treated
with ACTH, cortisone, hydrocortisone and related substances for various conditions.
They noted the common occurrence of "thinking disturbances" in these patients. This
observation was subsequently reiterated by other investigators (Hall, Popkin, Stickney, &
Gardner, 1979).
More recently, Keenan et al. (1996) conducted a dose-controlled cross-sectional
design comparing memory performance between prednisone treated, patients without
central nervous system involvement and normal controls. All patients in the
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experimental group had been taking between 5 and 40 mg of prednisone (M=17 mg/day)
daily for at least one year. Individuals were screened for the presence of any major
psychiatric disturbances, or any other conditions that may confound the interpretation of
results. The experimental group was heterogeneous and comprised individuals with
various rheumatological or neurological conditions such as scleroderma, myasthenia
gravis, rheumatoid arthritis, and chronic autoimmune hepatitis. Medical controls were
closely matched with the experimental group on diseases.
Primary neuropsychological tests included measures of declarative memory (i.e.,
WMS Logical Memory subtest, California Verbal Learning Test), and implicit memory
(i.e., Wordstem Completion Priming Task). Other domains assessed were visual spatial
abilities (Judgment of Line Orientation), verbal fluency (Controlled Oral Word
Association), non-verbal intellectual capacity (Raven's Progressive Matrices), non-verbal
memory (Spatial Recall) and attention (The Vigilance Test and Digit Span Forward).
The two groups were also administered a test of reading ability, and a disability inventory
questionnaire to rule out confounds of general intellectual ability and disease severity
respectively.
The treatment group recalled fewer bits of information on the Long-Delay
condition of WMS- Logical Memory subtest. Furthermore, a strong non-significant trend
was noted, wherein the control group outperformed the treatment group, on longdelayed memory from the California Verbal Learning Test. A significant difference on
the List Learning Discriminability Score, an index of recognition memory, was also
evident that favoured the control group. There were no significant group differences on
any other measures. Results of multiple regression analysis revealed that patient age
accounted for a significant proportion of the variance in Logical Memory recall scores.
More specifically, there was evidence of an age by duration interaction. Increasing age
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was associated with greater memory impairment in those patients taking the drug for up
to 3 years, but not for those taking the drug between 4 and 15 years.
The results, according to the authors, indicate a declarative memory impairment, which
was exacerbated with increasing age in individuals receiving chronic, moderate doses of
prednisone. A unique aspect of this investigation was the inclusion of an implicit memory task
that showed no group differences (i.e., the treatment group performed as well as controls). This
finding has been previously demonstrated (Kirschbaum et al., 1996; Lupien et al., 1994).
Brown et al. (2004) have recently replicated some of the findings of the Keenan
et al. (1996) investigation using a similar patient population. Their sample included 17
patients with various rheumatic diseases between the ages of 18 and 65 who had all
been receiving treatment with prednisone (5-30 mg/day, M=17 mg/day) for at least 6
months and healthy age and IQ matched controls. All participants were screened for the
presence of any current or past psychiatric problems; however, the investigators did
include some individuals in their study who had a current or past history of mood or
anxiety disorder secondary to GC therapy (n=10). These persons were included in order
to better reflect the general population of people taking GCs, at least some of who
develop such conditions. Primary neuropsychological tests included the RAVLT, Stroop
Color Word Test, TMTA and TMTB, and the National Adult Reading Test.
The treatment group performed significantly worse than the controls on the
RAVLT (Total words learned and 20-minute delayed recall) and the Stroop Color Word
Test. No significant differences were found on any other measures.
In a subsequent investigation, Brown et al. (2007) conducted a 4-year follow-up
study of corticosteroid-dependent patients and controls who all received mood,
cognitive, and in two cases, structural magnetic resonance imaging (MRI) assessments
at baseline (Brown et al., 2003; Brown et al., 2004). In total, seven prednisone treated
patients and six controls agreed to reassessment with psychiatric symptom and
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neurocognitive measures that included tests of verbal memory (RAVLT- total and
delayed recall), and attention (Stroop test). Findings indicated that cognition was
relatively stable over time in both groups. At the baseline assessment, the prednisone
treated patients had poorer performance on the RAVLT- total words recalled, and the
control group continued to outperform them at the follow-up assessment (i.e., the
performance of the prednisone treated group remained stable with regard to this score).
Although a trend toward worse performance on the Stroop test was evident, for the
prednisone treated group, it was not statistically significant. The authors concluded that
long-term prednisone therapy is associated with initial changes in memory that appear to
stabilize over time.
In a slightly different vein Monastero and colleagues investigated the prevalence
of cognitive impairment in patients with Behcet's disease without overt neurological
involvement (Monastero et al., 2004). Behcet's disease is a chronic multi-system
inflammatory disorder of unknown etiology. Their sample included 26 patients with
Behcet's disease and a healthy control group all of whom underwent a comprehensive
neuropsychological assessment. Of relevance to the present investigation, their sample
of patients with Behcet's disease was divided into an impaired and an unimpaired group.
Patients in the impaired group performed below the fifth percentile compared to age and
education corrected norms on tests from at least two cognitive domains.
A comparison of the impaired and unimpaired groups revealed a statistically
significant difference with regard to mean prednisone dose. Patients in the impaired
group were maintained on an average dose of 11.9 mg/day, while those in the
unimpaired group were maintained on an average dose of 2.8 mg/day (Monastero et al.,
2004).
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Conclusions
There is some evidence to suggest that prolonged moderate to high-dose
therapy with GCs may have an adverse impact on declarative memory. This impact may
vary as a function of age and duration of treatment, with older individuals treated for
between one and three years being more sensitive to the adverse cognitive impacts of
GCs. There is also modest evidence to suggest that doses in the lower end of the
moderate range can have an adverse effect on cognition. There is a need for studies
that not only extend the findings of those abovementioned with regard to memory, but
also examine executive functions more closely using different patient populations, and
different doses of GCs administered therapeutically (Brown et al., 2004; Dorn & Cerrone,
2000). As it stands, the findings with regard to declarative memory deficits after
therapeutic treatment with GCs have been validated primarily in patients with Systemic
Lupus Erythematosus (Denburg, Carbotte, & Denburg, 1994; Harrison & Ravdin, 2002).
General Conclusions
End-stage renal disease is a problem that is increasing worldwide. The first
treatment choice for these patients is dialysis, either HD or PD. However, both these
treatments are associated with a variety of complications (i.e., access infections,
increased cardiovascular risk, and uremia). The preferred method of treatment for these
patients is renal transplantation; however, access to viable organs and a shortage of
living organ donors continue to be obstacles. There is extensive evidence
demonstrating improved quality of life after transplantation compared to dialysis.
Transplanted patients must comply with a wide array of post-transplant
immunosuppressive agents. There is only modest evidence to suggest that these
agents may have an impact on cognitive functioning, and this remains an avenue for
future inquiry. Corticosteroids, and more specifically GCs, have traditionally been a vital
part of the post-transplantation regimen, regardless of the organ transplanted. Although
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there is currently the potential to manage some patients without steroids posttransplantation, particularly post-renal transplantation, epidemiological investigations
indicate that steroids continue to be a staple for the majority of solid organ transplant
recipients. Overall, the neurocognitive sequelae of end-stage renal disease,
transplantation, and post-transplant immunosuppression require further investigation.
There is a wide body of literature addressing the impacts of GCs on cognitive
functioning; however, the vast majority of these investigations have focused on states of
excessive hyercortisolemia with regard to declarative memory. Furthermore, although
the impact of acute, moderate to high doses of exogenous GCs on memory has been
adequately documented, very little is known about the long-term ramifications (i.e.,
greater than one year) of exogenous, low dose, GC administration.
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III. RATIONALE AND OBJECTIVES OF THE CURRENT INVESTIGATION
Rationale For the Present Investigation
There remain a need for investigations examining the long-term (i.e., greater than
one year) impact of low dose exogenous GCs on cognitive functioning. Clinical
populations for whom this situation may be directly relevant include those with certain
rheumatic conditions and patients who are post solid organ transplantation. There
appear to be only a couple of investigations in the literature thus far that have attempted
to examine this phenomenon, and both have utilized heterogeneous samples of patients
with various rheumatic and neurological conditions (Brown et al., 2004; Keenan et al.,
1996). Furthermore, both investigations examined the impact of moderate to high doses
of exogenous GCs (i.e., 16-20 mg/day) on cognitive functioning. Although this would
certainly seem appropriate given the clinical populations utilized, it may not be applicable
to recipients of solid organ transplants, the majority of whom receive chronic low doses
of exogenous GCs (i.e., 2 to 10 mg/day prednisone). Theoretically, it is possible that
even low doses of exogenous GCs delivered chronically may impair certain elements of
cognitive functioning and the effects may be more deleterious in some older individuals
(60-80 years old). There appears to be modest support for this hypothesis in the human
literature utilizing samples of healthy individuals and geriatric patients (Keenan et al.,
1996; Lupien et al., 1996; MacLullich et al., 2005; Newcomer et al., 1994).
The purpose of the present cross-sectional investigation was to examine
cognitive functioning with regard to chronic low dose GC therapy using a sample of renal
transplant recipients. The chronic steroid treatment group (CS group) included
individuals who had been receiving low dose prednisone chronically for at least six
months at the time of the study. The steroid avoidance group (SA group) consisted of
renal transplant recipients in steroid avoidance protocols. Although some of these
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individuals may have received high dose GCs 2-3 days after transplantation to prevent
acute rejection, they had been steroid free for at least six months at the time of the
study.
These two groups were compared with regard to their performance on a series of
neuropsychological measures, with the primary cognitive domains of interest being
declarative memory and complex attention. The majority of the domains were
represented by composite category averages consisting of combined scores on different
tests related to the same functional domain (e.g., the domain of attention may have
consisted of scores on the TMTA and the PASAT).
The investigation was carried out to further elucidate the impact of chronic GCs
administered therapeutically, and to aid in the medical management of renal transplant
recipients, many of who deal with the ramifications of chronic exogenous GC therapy.
Primary Objectives
The effect of prednisone on declarative memory
To replicate the findings of previous investigators (i.e., Brown et al., 2004;
Keenan et al., 1996) regarding the adverse effects of exogenous GC administration on
declarative memory.
The effect of prednisone on complex attention
To further elucidate the effects of exogenous GC administration on particular
aspects of complex attention (i.e., inhibition/disinhibition, working memory, set-shifting).
The impact of patient age, prednisone duration and dose on declarative memory
To examine the contribution that patient age, duration of GC administration, and
drug dosage make to contributing variance in the declarative memory composite score
for individuals in the CS group.
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Primary Hypotheses
The effect of prednisone on declarative memory and complex attention
Hypothesis 1:
Based on the investigations conducted by Keenan et al. (1996) and Brown et al.
(2004), it was expected that the performance of the CS group would be significantly
worse than that of the SA group on the declarative memory composite domain.
Specifically, it was predicted that the performance of the SA group would be significantly
better than that of the CS group on the immediate and delayed recall components of the
WMS-III Logical memory I and II subtests (Keenan et al., 1996; Newcomer et al., 1994).
It was further predicted that the SA group would outperform the CS group on the
RAVLT- Total words trials 1 -5, 20 minute delayed recall scores, and recognition
discriminability (Brown et al., 2004; Keenan et al., 1996).
Hypothesis 2:
Based on the few investigations that have examined complex attention (i.e.,
Brown et al., 2004; Lupien, Gillin, & Hauger, 1999; Young et al., 1999), it was predicted
that there would be significant group differences on this composite domain. The
performance of the SA group would be significantly better than that of the CS group on
measures assessing working memory, inhibition/disinhibition, and set-shifting.
Specifically, it was predicted that the SA group would demonstrate significantly greater
scores on the WAIS-III Letter-Number sequencing subtest, WAIS-III Digit Span
backward, and WMS-III Spatial Span backward tests than the CS group. Moreover,
members of this group were expected to demonstrate fewer errors and a faster time to
completion on the final trial of the Stroop colour word test, and fewer total errors on the 1
and 2-back conditions of the N-back test. Finally, it was predicted that they would
demonstrate a faster time to completion and fewer errors on the TMTB.
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The impact of prednisone on simple attention and processing speed
Hypothesis 3
Based on the Keenan et al. (1996) investigation, participants in the SA group
were not predicted to significantly outperform those in the CS group with regard to the
simple attention or processing speed composite scores.

The impact of patient age, prednisone duration and dose on declarative memory
Hypothesis 4
Patient age and duration of steroid treatment, but not dosage, were expected to
predict a significant amount of variance in the declarative memory composite score for
participants in the CS group. Specifically, it was predicted that increasing age and
longer treatment duration would be associated with greater memory impairment. GC
dosage was not predicted to impact the declarative memory composite score because
all patients within the CS group were known to be within a relatively narrow band of
dosing (i.e., between 2 and 10 mg/daily).
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IV. METHODOLOGY
Participants
Participants received renal transplants through the Harper University Hospital
solid organ transplantation program between the years 2002 and 2007. Initially, subjects
were recruited for their possible inclusion in the study by one of the transplant nurses
and the student researcher. Participants completed informed consent procedures in
accordance with Health Insurance Portability and Accountability Act (HIPAA) guidelines,
Wayne State University Human Investigations Committee regulations and University of
Windsor Research Ethics Board regulations. Participants in both CS and SA groups
were at least six months post-renal transplantation. Participants in the CS group had
been receiving chronic low dose (i.e., 2-10 mg/day) prednisone since transplantation,
whereas subjects in the SA group had been rapidly weaned off prednisone within the
first few days following transplantation (avoidance).
The primary nephrologist decided whether an individual would receive chronic
steroid medication. Although the protocol for deciding when a patient will receive
steroids post-transplant varies, at Harper University Hospital the decision was made
prior to transplantation and was based, almost exclusively, on immunologic variables
which do not always correlate well with disease severity. Whenever possible,
participants in both groups were matched on other medications administered as part of
the post-transplantation regimen, such as tacrolimus and mycophenolate mofetil. Due to
literature documenting a negative association between plasma levels of cyclosporine
and aspects of cognitive functioning, renal transplant recipients maintained on
cyclosporine were excluded from the study (Griva et al., 2004).
Other inclusion criteria for participants in both CS and SA groups were as
follows: chronological ages between 18 and 60 years inclusive, a current level of
adequate renal function (as assessed by the Cockroft-Gault modification equation)
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(participants were excluded if they demonstrated <30% functioning based on this
equation, or if they obtained serum creatinine values of greater than 2.0 during their two
most recent clinic visits), and English as their primary language, or at least fluency in
written and spoken English. Values of renal function could not be obtained on the same
day of neuropsychological testing for all participants. To provide a reliable estimate of
renal function, the GFR values (as estimated from the Cockroft-Gault equation) from the
two most recent clinic visits were averaged.
Exclusionary criteria targeting confounds to the interpretation of results included
uncorrected visual impairment (participants were told to bring reading glasses if they
wore them), color blindness, uncorrected hearing loss, transplantation prior to 2002,
documented intellectual disability, pregnancy or treatment with high-dose estrogens,
cushing's syndrome, uncontrolled diabetes mellitus (excluded if hemoglobin A1C>14%
for the average of their two most recent clinic visits), trauma, fever, or dehydration within
the past two weeks, temporal lobe epilepsy, addison's disease, hypopituitarism or other
endocrine diseases other than diabetes, HIV nephropathy, documented delirium during
the 6 months prior to the study, current alcohol or drug abuse, treatment with
cyclosporine, major psychiatric illness (based on documentation of an Axis I disorder on
chart review, or a T-score of greater than 70 on the Global Severity Index of the Brief
Symptom Inventory (BSI)). With regard to psychiatric history, if a patient exhibited a
global severity index T-score between 63 and 70 on the BSI, they were administered a
list of additional questions pertaining to symptoms of psychological disturbance. Testing
was discontinued if the given patient endorsed a certain number of symptoms
suggestive of an active psychological condition. It should be noted that these questions
were asked even when a given patient obtained a GSI T-score of 70 or above (i.e., in the
case of automatic discontinuation). Most of the other information was gathered through
a review of medical charts and via interviews with the participants conducted prior to
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testing. Whenever possible, participants were tested on the day of a regularly scheduled
clinic appointment; otherwise, they came in for testing on a separate occasion.
Moreover, an attempt was made to test all participants during the same time of day,
preferably in the afternoon, to better address the effect of GC therapy on cognition. This
was done in accordance with the abovementioned literature that has demonstrated a
consistent temporal variation in endogenous Cortisol, with the trough occurring during the
afternoon in humans (Lupien et al., 2002b; Newcomer et al., 1994).
Of the approximately 370 available cases in the renal transplant database at
Harper University Hospital, 101 (26.5%) were excluded because patients had an age
greater than 60. An additional 100 (26.3%) cases were discarded because patients
were transplanted prior to 2002. Fifteen patients (4%) were excluded based on
information from their records indicating the presence of an active psychiatric
disturbance treated with medication. Approximately eighteen participants (5%) were
excluded due to the presence of other disorders, outlined in the exclusionary criteria
including lupus, seizures treated with medication, cancer of the brain, blindness,
documented evidence of an intellectual disability, and recent motor vehicle accidents
with documented evidence of head injuries. Twenty-five participants (6.5%) were
excluded because they had serum creatinine levels greater than 2.0 during their two
most recent clinic visits. Forty-two participants (11%) were excluded because they were
on cyclosporine. Eleven patients (2.9%) were excluded because their Hemoglobin A1C
values suggested uncontrolled diabetes. Approximately ten participants (2.6%) were
excluded because they failed to show up for their appointments, refused to participate in
the study outright, moved from the city, or were put back on dialysis. Approximately
three patients (0.8%) were excluded on the basis of scores below cutoffs on the
screening criteria. Finally, one person in the CS group was excluded on statistical
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grounds and will be described further in the results section. The final sample contained
thirty-nine participants, 17 in the CS group and 22 in the SA group.
Procedure
Once potential participants were recruited, the student researcher examined their
medical records to determine their suitability for inclusion in the study. Participants were
tested by the student researcher or his research assistant in a testing room within the
Harper University Hospital renal transplantation clinic facilities. Whenever possible, the
testing was dovetailed with their regular clinic appointment to avoid a separate trip to the
clinic. Prior to testing, a short interview was conducted to gather relevant information not
available in medical charts such as handedness, primary language, and years of
education. Having participants identify the colours on one card of the Stroop Test
assessed the presence of adequate colour recognition. To test auditory acuity, the
examiner stood behind the participant and read a sentence aloud, that was repeated
back by the participant. A formal test of English fluency was not administered; however,
this information was gathered through the chart review and a discussion with the patient.
Testing commenced with the administration of the screening measures. The student
researcher or his research assistant scored these measures immediately to further
determine participant suitability. If a potential participant was determined unsuitable at
this point, they were paid ten dollars (half the total remuneration) and the reason for their
exclusion was explained. If the results of the screening measures were within
parameters, the rest of the testing was completed, and participants were paid twenty
dollars.
The consent form explained that participants could go to the University of
Windsor Ethics website to access the overall results of the study. The consent form is
included in the Appendix B. Moreover, each participant was given a brief one-page
summary of his/her performance on testing at the time of his/her next clinic appointment.
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The feedback form was co-signed by the transplant psychologist. Where results of the
study for a given individual revealed either a clinically significant cognitive deficit (i.e., an
age-adjusted T-score greater than 1.5 standard deviations below the mean on a
composite of memory, or a composite of complex attention), or evidence of a possible
psychiatric condition (as denoted by a GSI T-score of greater than 70, or a T-score of
between 63 and 70 with additional endorsement of screening questions suggestive of a
possible psychological condition), the appropriate transplant nephrologist was contacted
and made aware of this by the student researcher under the supervision and guidance of
the transplant psychologist. These additional questions are included in Appendix C. An
appropriate referral was made for the participant as needed at the time of his/her next
regular clinic visit. As such, participants were made aware that their individual study
results could be divulged to their primary transplant nephrologist.
Materials
The measures to be administered were sorted into the composite categories of
declarative memory, complex attention, simple attention, and processing speed. A
detailed description of all the tests utilized is presented in Table 2. The standard
psychometric properties for the published tests are presented in Appendix D. The
sources of the psychometric information are presented in Appendix E. Other tests
administered as part of the screening process included: the BSI (Derogatis &
Melisaratos, 1983), a questionnaire used to screen for psychiatric disturbance, the Wide
Range Achievement Test- 3rd Edition (WRAT-3) reading Subtest (Wilkinson, 1993) used
to estimate the pre-morbid level of general intellectual functioning, and, where required,
the CAGE4, a four item measure frequently used to screen for alcohol abuse. Table 3
details the specific test scores comprising each composite category.
Although many of the cognitive measures utilized were related in some way to
more than one of the abovementioned composite categories, each test/subtest was
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included within the one composite category that appeared most appropriately related to
the task demands of the particular test. Moreover, there was some evidence from prior
research to sort the tests in such a manner (Jassal, Devins, Chan, Bozanovic, & Rourke,
2006). The composite categories were chosen on the basis of the literature review that
revealed the sensitivity of these areas of cognitive functioning to the effects of steroids
(Brown et al., 2004; Keenan et al., 2004; Newcomer et al., 1994). Similarly, the specific
tests within the domains were chosen on the basis of the literature review that indicated
their sensitivity to the effects of steroid exposure. For example, Keenan and colleagues
demonstrated that moderate to high dose prednisone exposure caused decreased
performance on the Logical Memory subtest of the Wechsler Memory Scale. Similarly,
Brown and colleagues demonstrated decreased performance on the Stroop Colour Word
test after moderate doses of prednisone exposure (Brown et al., 2004; Keenan et al.,
1996).
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V. FINDINGS
The formation of composite category scores
Because there was no normative base for all the measures in the battery, raw
scores from each test were converted to z-scores based on the performance of all the
participants in the study. The z-scores were averaged to form the required composite
category scores. Z-scores were used for all statistical analyses. Where required, zscores were adjusted so that, for all tests, positive z-scores denote better performances,
while negative z-scores denote worse performances.
Description of statistical analysis and rubric for interpretation of strength of association
For the purpose of group-wise comparisons with regard to the cognitive
dependant variable scores, variables were considered to be normally distributed, if the
skewness and kurtosis values were between (-1.0 to +1.0) and if the result of the
Shapiro-Wilk's test was not significant. Due to the fact that oppositely skewed variables
can significantly impact the t-test with small sample sizes, boxplots and histograms were
examined to ensure that, variables were skewed in the same direction, or were skewed
in the opposite direction to a minimal extent.
Correlations were interpreted with regard to strength according to the criteria set
forth by Cohen that dictates the following interpretations: weak (+/-.10 to +/-.29);
moderate (+/- .30 to +/- .49); and strong (+/- .50 to +/-1.0) (Cohen, 1988). All statistical
analyses were conducted using SPSS version 14.0 for windows (SPSS Inc., Chicago, IL,
USA).
Descriptive information by group on demographic, medical, and neuropsychological
variables
Descriptive information for the relevant demographic and medical variables for
participants in each of the two post-transplant groups is presented in Table 4 and
illustrates that the two groups were relatively equivalent in terms of these variables.
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Participants in the CS group were maintained on an average of 4.4 mg of prednisone
(2.5 - 7.5 mg) for an average of 25.7 months (6 - 47.2 months). Wherever possible, ageadjusted scaled scores and age-adjusted t-scores were computed for
neuropsychological test scores and this information is presented in Table 5. The specific
published norms that were used to calculate the various age-adjusted scaled scores and
t-scores are presented in Table 6. As can be seen from Table 5, based on age-adjusted
normative data, participants in both study groups performed in the low-average to
average range across tests. On an absolute basis, participants in the CS group
outperformed participants in the SA group on the majority of tests.
Figure 1 depicts the average z-scores from each of the four composite domains
for the CS and SA groups. Table 8 displays the average z-scores on each of the tests
used to form the cognitive composite domains for the CS and SA groups. As noted in
Table 5, for scores relative to external normative groups, the z-scores in Table 8 also
reveal the better performance of the CS group relative to the SA group on the majority of
measures.
Group comparisons on continuous demographic and medical variables
Either independent samples t-tests, or Mann Whitney-U tests were used to
compare the two groups on the following continuous demographic and medical
variables: duration of dialysis prior to transplant, GFR, mean mycophenolate mofetil
dose, mean tacrolimus dose, systolic blood pressure, diastolic blood pressure, months
since transplant, WRAT-3 reading score, BSI (GSI) score, age, and years of education.
A Bonferroni-Holm's correction was applied to group-wise comparisons to control for the
inflated Type I error rate associated with multiple comparisons. Given the small sample
size in the present study and the chance of potentially excluding clinically meaningful
data with too stringent a correction for multiple comparisons, the Bonferroni-Holm's
technique was used instead of the Bonferroni technique, which is more conservative. A
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series of Spearman's correlations were calculated to examine the relationship between
the various continuous medical and demographic variables and the four cognitive
composite domain scores. A Larzelere-Mulaik correction was applied to reduce the
inflated Type I error rate associated with multiple correlations. The Larzelere-Mulaik
procedure is an extension of the Holm's procedure used for controlling the Type I error
rate associated with conducting multiple correlations. Where a particular continuous
demographic or medical variable differed significantly between the groups and was
significantly associated (p < .05) with one or more of the cognitive domain composite
scores, that variable was treated as a covariate in an analysis of covariance (ANCOVA)
for the cognitive composite domain in question. Where no covariates were identified, the
cognitive composite domain scores were compared using a series of one-tailed
independent sample t-tests, for normally distributed variables, or Mann-Whitney U-tests
for non-normally distributed variables. Analyses were assessed at the p< .05 (onetailed) level of significance.
Due to violations of normality, a series of Mann-Whitney U tests were conducted
to examine group differences with regard to dialysis duration prior to transplant, dose of
mycophenolate mofetil, dose of tacrolimus, and the WRAT-3 reading score. Group-wise
comparisons for the rest of the continuous medical and demographic variables were
assessed via independent samples t-tests. Results of these analyses are presented in
Table 4 and suggest that, after correcting for multiple comparisons, the only variable that
differed significantly between the groups was mean dose of mycophenolate mofetil per
day, U = 85, p = .00. An examination of Table 4 indicates that participants in the SA
group were maintained on a significantly higher dose of this drug than participants in the
CS group. The other demographic and medical variables did not differ significantly
between the two groups. However, before controlling for multiple comparisons, the
group difference with regard to years of education was also statistically significant.
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An examination of the scatterplots between the various continuous demographic
and medical variables and the four cognitive composite scores revealed a non-linear
relationship between age and the simple attention composite score. All the other
relationships appeared to be linear. The results of a series of Spearman's correlations
between the various continuous demographic and medical variables and the four
cognitive composite z-scores for the entire sample are presented in Table 7. After
correcting for multiple correlations, WRAT-3 reading was positively correlated with the
complex attention composite score, rs (39) = .55, p= .00, and duration of dialysis prior to
transplant was negatively correlated with the processing speed composite score, rs (39)
= -.57, p= .00. There were no significant associations between any of the other
continuous demographic or medical variables and the cognitive composite scores.
Although not statistically significant after controlling for multiple correlations, the
following continuous medical or demographic variables demonstrated moderate to
strong positive associations with at least half of the cognitive composite scores: WRAT-3
reading, months since transplant and years of education. This suggests the hypothesis
that overall cognitive efficiency post-transplantation appears to be associated with higher
reading levels, greater education and a longer time since transplant. Similarly, although
not statistically significant after controlling for multiple correlations, duration of dialysis
prior to transplant exhibited moderately negative associations with the majority of
cognitive composite scores suggesting the hypothesis that a longer bout of dialysis prior
to transplant is associated with decreased cognitive efficiency post-transplantation. To
further examine the non-linear relationship between age and simple attention, four
roughly equivalent age categories were created and the non-linear coefficient of
correlation was calculated, q = .14. The squared coefficient was found to be nonsignificant, rf= .02, p >.05.
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Due to the fact that none of the continuous medical or demographic variables
correlated significantly with the cognitive composite scores and differed significantly
between the two groups, the majority were not included as covariates in primary
comparisons of the SA and CS groups with regard to cognitive functioning. However,
before adjusting for multiple comparisons, the group difference with regard to years of
education was statistically significant. Moreover, this variable exhibited a moderate
correlation with the complex attention composite score, rs (39) = .36, p = .02. Therefore,
this variable was included as a covariate when comparing the two groups with regard to
the complex attention composite score.
Group Comparisons on categorical demographic and medical variables
A series of chi-square tests were conducted to examine the distribution of the
categorical demographic and medical variables between the two groups. The variables
included gender, handedness, proportion of African Americans, proportion of European
Americans, proportion with hypertension, proportion receiving cadaveric transplants,
proportion who underwent HD prior to transplantation, and the number of people treated
with beta blockers. Where the chi-square test was significant for a particular variable, a
Kendall Tau correlation was conducted between the variable in question and the four
cognitive composite domain scores. These analyses were conducted to identify
categorical demographic and medical variables that would confound factors to the
interpretation of the results.
Table 4 details the results of chi-square analyses conducted on the categorical
demographic and medical variables. None of the chi-square tests reached statistical
significance, suggesting that all the categorical demographic and medical variables were
independent of group membership. For handedness and proportion of European
Americans, Fisher's Exact Test was conducted because some cell sizes in the chisquare were less than five. The result of Fisher's Exact Test was in accordance with the
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chi-square test for both of these variables and was non-significant. The results of these
analyses suggested that the categorical medical and demographic variables would not
serve as significant confounds to the interpretation of results.
Screening for outliers
Before comparing the two groups with regard to cognition, all the dependant
variables were screened for outliers. Based on the outlier analysis, one person was
excluded from the CS group as he/she appeared to be an outlier on several cognitive
measures (at least six). A further inspection of this profile suggested that this person
was maintained on a different formulation of the antimetabolite, mycophenolate mofetil.
Although it was unlikely that this difference could account for his/her discrepant
performance on several cognitive measures, it was clear that the inclusion of this case
could confound the findings. It should be noted that the analyses described in the
previous section with regard to the demographic and clinical variables were conducted
after this case was excluded. For the remaining cases, those outliers that were greater
than 1.5 standard deviations from the mean were modified by a procedure wherein the
outlying scores were assigned a score one point higher or lower than the next most
extreme score in the distribution. This technique has been recommended in situations
where there are a small number of outliers (Pedhazur, 2002). Approximately 10 data
points were modified in this manner.
Inspection of the distribution of the cognitive test scores
To compare the two groups on specific tests, a series of one-tailed independent
sample t-tests, for normally distributed scores, or Mann-Whitney U-tests for non-normally
distributed scores were conducted. Unless otherwise noted, a Bonferroni-Holm's
correction was applied to these analyses to control for the inflated Type I error rate
associated with multiple comparisons. Analyses were assessed at the p< .05 (onetailed) level of significance.
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The impact of prednisone on performance in the four cognitive domains
Table 8 details the results of one-tailed group-wise comparisons on three of the
four cognitive composite domains. Due to violations of normality, scores on the
processing speed domain were compared using a Mann-Whitney U test whereas the
declarative memory and simple attention domain scores were compared using one-tailed
independent samples t-tests. The one-tailed test reached statistical significance with
regard to the domain of simple attention, t (37) = 2.52, p = .02 (one-tailed). However, an
examination of Figure 1 revealed that the direction of the result was opposite to what
was predicted (i.e., participants in the CS outperformed those in the SA). To further
examine this result, an ANCOVA was conducted with months since transplant as a
covariate. Months since transplant was chosen because of the moderate association it
exhibited with the simple attention domain, rs (39) = .42, p = .01 (Table 7). The data
were screened with regard to violations of the assumptions of normality, linearity,
homogeneity of variance and homogeneity of regression slopes. After controlling for
months since transplant, there was no reliable group difference with regard to the simple
attention composite score, F (1, 36) = .94, p = .08, partial eta-squared =. 10. Group
differences with regard to the processing speed and declarative memory composite
scores were not significant.
To compare the two groups with regard to the complex attention composite
score, an ANCOVA was conducted with years of education as the covariate. After
controlling for years of education, there was no significant group difference on the
complex attention composite domain, F (1, 36) = .94, p = .34, partial eta-squared = .03.
Comparisons of the various test scores comprising each cognitive composite
domain are presented in Table 8. Due to violations of normality, slightly less than half of
the test scores were compared using one-tailed Mann-Whitney U tests with BonferroniHolms corrections. The remainder were compared using one-tailed independent
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samples t-tests. After correcting for multiple comparisons, there were no significant
group differences with regard to any of the test scores. However, before correcting for
multiple comparisons, scores with regard to TMTA (time), digit span backward, letternumber sequencing, and stroop colour-word (time) were significantly better for the CS
group than the SA group. Likewise, before correcting for multiple comparisons, the
recognition discriminability score was significantly better for the SA group than the CS
group.

The impact of patient age, prednisone duration and dose on declarative memory
Statistical analyses with regard to the third goal were conducted on the CS
group. Therefore, z-score composites for all the variables were re-calculated based on
the mean of the CS group. A series of correlations were conducted between current
kidney function as assessed by the GFR, systolic blood pressure, diastolic blood
pressure, years of education, duration of dialysis, mean mycophenolate mofetil dose,
mean tacrolimus dose, WRAT-3 reading score, months since transplant, and the
declarative memory z-score composite. This was done to assess the possible impact of
the continuous demographic and medical variables on declarative memory. Similarly, a
series of Kendall's Tau correlations were conducted to examine the relationship between
the categorical demographic and medical variables and the declarative memory
composite score. Where the correlation was statistically significant, the variable in
question was controlled for in a multiple regression analysis. Where these variables
failed to significantly correlate with the declarative memory composite score a standard
regression was conducted using age, prednisone duration, and prednisone dose as the
independent variables.
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Selection of appropriate predictors for regression analyses
To ascertain if the drug effect on the declarative memory z-score composite was
influenced by patient age, dose or duration of steroid treatment, a sequential multiple
regression was conducted. Before conducting the analysis, the data were screened for
violations of assumptions of normality, linearity, homoscedasticity and independence of
residuals. To control for their effect, the demographic and medical variables
abovementioned that significantly (p < .05) correlated with the declarative memory zscore composite were entered in the first block of the sequential multiple regression.
Following this, patient age, treatment duration and drug dosage was entered into the
model. Where the medical, or demographic variables failed to correlate significantly with
the declarative memory z-score composite, a standard multiple regression was
conducted using patient age, duration of prednisone treatment, and prednisone dose as
the independent variables. Again, the results of all individual analyses within the model
were assessed at the p< .05 level of significance.
The results of correlations between GFR, systolic blood pressure, diastolic blood
pressure, years of education, months since transplant, WRAT-3 reading, duration of
dialysis prior to transplant, mean mycophenolate mofetil dose, mean tacrolimus dose
and the declarative memory composite score for participants in the CS group are
presented in Table 9. Although none of the correlations reached statistical significance,
there was a trend towards significance in the positive direction for the relationship
between months since transplant and declarative memory, rs(17)= .48, p = .05, and in
the negative direction for the relationship between dialysis duration prior to transplant
and declarative memory, rs (17) =-.44, p = .07. Table 10 presents the results of
Kendall's Tau correlations between the categorical demographic and medical variables
and the declarative memory composite score. None of these correlations reached
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statistical significance suggesting that these variables would not have to be included in
any regression analyses.
Due to the small sample size of the CS group (n=17), a decision was made to
conduct a standard regression analysis with a minimum number of predictors. A series
of correlations between mean prednisone dose, prednisone duration, patient age, and
the declarative memory composite score were conducted to select appropriate
predictors. An examination of the scatterplots between each of the independent
variables and the declarative memory composite score revealed a non-linear relationship
between prednisone dose and declarative memory. The other relationships appeared to
be linear in nature and the results of these analyses indicated that prednisone duration
was significantly associated with the declarative memory composite score, rs(17) = .49,
p = .04, whereas patient age was not, rs (17) = .25, p = .34. The positive association
between prednisone duration and the declarative memory composite score was
unexpected. Therefore, a series of correlations between prednisone duration and the
other continuous demographic and medical variables were conducted to examine the
possibility of a moderating variable. After controlling for multiple comparisons, there was
a strong positive relationship between months since transplant and prednisone duration,
rs (17) = .94, p = .00. The results of the other correlations did not reach statistical
significance. The finding of a strong positive association between months since
transplant and prednisone duration was not surprising as the majority of patients in the
CS group (11/17) had been initiated on prednisone immediately post-transplantation.
The other patients were initiated on prednisone a mean of 3.8 months posttransplantation. A partial correlation between prednisone duration and declarative
memory, controlling for months since transplant, was not statistically significant, r123(17)
= .22, p = .41. Based on this analysis, prednisone duration was not included as an
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independent variable in a regression analysis as the interpretation of results would be
confounded by its strong correlation with months since transplant.
The scatterplot of the nonlinear relationship between prednisone dose and
declarative memory for participants in the CS group is presented in Figure 2. It was
evident that the one data point at 7.5 mg of prednisone was modifying the relationship
between the variables (i.e., with that point removed the relationship between prednisone
dose and memory appeared to be negative and linear as opposed to curvilinear). The
clinical significance of this one data point was unclear; therefore, the data were analyzed
with its inclusion and exclusion. The non-linear relationship between prednisone dose
and declarative memory was calculated (with the inclusion of the influential data point)
and found to be reasonably strong, q = .648. Likewise, the linear relationship (with the
point excluded) between prednisone dose and declarative memory was significant, rs
(16) = -.63, p < .05, indicating an association between a higher dose of prednisone and a
poorer memory score. To check for the possibility of a variable moderating the
relationship between prednisone dose and declarative memory, a series of Spearman's
correlations (with the exclusion of the influential data point) and a series of eta
coefficients (with the inclusion of the point) were conducted. Table 11 presents the
results of Spearman's correlations (with the exclusion of the influential data point) and
the corresponding eta-squared values (with the inclusion of the point) for the
relationships between prednisone dose and the other continuous medical and
demographic variables. Although none of the correlations reached statistical
significance after controlling for multiple correlations, there was a strong negative linear
correlation between months since transplant and prednisone dose, rs(16) = -.62, p = .01,
indicating an association between a greater time since transplant and a lower dose of
prednisone. These analyses indicated that the vast majority of the continuous medical
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and demographic variables did not appear to be modifying the relationship between
prednisone dose and declarative memory.
The results of these preliminary analyses suggested that the most appropriate
predictor for regression was prednisone dose. Furthermore, based on the findings of a
trend towards significance for the relationship between duration of dialysis prior to
transplant and declarative memory, rs (17) = -.44, p = .07, a decision was made to
include this variable as an independent variable in a regression analysis. Due to the
nonlinearity of the relationship between prednisone dose and declarative memory, two
separate analyses were conducted.
The influence of dialysis duration prior to transplant on post-transplant declarative
memory
An initial standard regression of the effect of dialysis duration prior to transplant
on the declarative memory score was conducted to examine violations of linearity,
homoscedasticity, normality, and to check for the presence of outliers. The normal
probability plot was acceptable as was the scatterplot of the residuals. These plots are
presented in Figure 3. The overall model was statistically significant, F (1, 15) = 4.83, p
= .04, and suggested that duration of dialysis prior to transplant predicted almost 20% of
the variance in the declarative memory score post-renal transplantation (Adjusted R2=
. 19). The regression table for the model is presented in Table 12. Specifically, the
direction of the Spearman's correlation indicated a trend wherein greater duration of
dialysis prior to transplantation was associated with poorer declarative memory posttransplantation, rs(17) = -.44.
The influence of prednisone dose on post-transplant declarative memory
The relationship between prednisone dose and declarative memory was initially
analyzed with the exclusion of the influential data point. Prednisone dose appeared to
be categorical in its distribution with people either receiving 2.5 mg, or 5 mg of
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prednisone. A separate variable was created that represented these two levels of the
drug. It was clear from its strong correlation with prednisone dose, rs (16) = -.62, p = .01,
that months since transplant would have to be controlled. Initial screening for its
inclusion as a covariate in an ANCOVA revealed its moderate degree of correlation with
the declarative memory composite score, rs (16) = .49, p = .06. Further screening
demonstrated that months since transplant exhibited a linear relationship with the
declarative memory score for participants receiving 2.5 and 5 mg of prednisone. A
formal test for the violation of homogeneity of regression slopes was not significant, F (1,
12) = .58, p = .46, indicating that months since transplant exhibited a similar relationship
with the declarative memory score for participants receiving both drug dosages. A
univariate ANCOVA was conducted with prednisone dose as the independent variable,
months since transplant as the covariate, and the declarative memory score as the
dependent variable. After controlling for months since transplant the difference in the
memory scores of patients receiving 2.5 versus 5 mg of prednisone was not statistically
significant, F (1, 13) = 4.60, p = .05. However, it exhibited a strong trend towards
significance. Specifically, an examination of the estimated marginal means suggested
that participants receiving 5 mg of prednisone had relatively worse declarative memory
scores (M = -.31, SD = .22) compared to participants receiving 2.5 mg of prednisone (M
= .61, SD = .34). Overall, prednisone dose accounted for approximately 26% of the
variance in the declarative memory composite score, (partial-eta squared = .26). On the
contrary, after adjusting for dose of prednisone, months since transplant accounted for
approximately 6% of the variance in the declarative memory composite score, (partialeta squared = .59).
Overall, the results of this analysis suggested that prednisone dose accounted
for a noteworthy portion of the variance in the declarative memory composite score after
controlling for the effect of months since transplant. Moreover, patients receiving 5 mg
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of prednisone appeared to have relatively poorer declarative memory scores compared
to patients receiving 2.5 mg of prednisone after controlling for months since
transplantation.
To ascertain the impact of the influential 7.5 mg data point, a test of non-linearity
was conducted that was statistically significant indicting some mild degree of nonlinearity in the model with this value included, F (1, 14) = 4.92, p = .04. The value of
non-linear association was calculated, q = .648 and the squared coefficient was found to
be statistically significant, indicating that prednisone dose predicted a significant amount
of variance in the declarative memory composite score, rf= .42, p < .05. Due to the
very small sample size, a polynomial regression was not conducted to ascertain the
possible nature of the non-linear relationship; however, an examination of the scatterplot
suggested the possibility of a quadratic relationship. The results from the non-linear
model were interpreted with caution as the coefficient of non-linear association is
significantly influenced by small cell sizes and in this case, the influential point
represented a cell size of just one.
Exploratory analyses
Based on the statistical analyses carried out to address the first three goals, it
was decided to conduct additional analyses to further explore the data. First, the
analyses revealed a significant negative relationship between duration of dialysis prior to
transplant and the post-transplant declarative memory composite score for participants
in the CS group. A Spearman's correlation between these two variables for the SA
group was not significant, rs (22) = -.39, p = .11. Similarly, the relationship between
months since transplant and declarative memory for participants in the SA group was not
statistically significant, rs (22) = .20, p = .35, but was in the positive direction. Finally, the
relationship between WRAT-3 reading and declarative memory for participants in the SA
group was strongly significant, rs (22) = .55, p = .01.
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Table 7 illustrates a moderate to strong relationship among WRAT-3 reading,
months since transplant, and duration of dialysis prior to transplant with at least half of
the cognitive composite domain scores for the entire sample. To further explore this
finding, a composite score reflecting a measure of general cognitive efficiency was
calculated by averaging the four major cognitive composite z-scores (i.e., declarative
memory, simple attention, complex attention, and processing speed) for the entire
sample (N = 39). A standard multiple regression was conducted with WRAT-3 reading,
months since transplant, and duration of dialysis as independent variables and the
global measure of cognitive efficiency as the dependant variable.
The overall model was statistically significant, F (3, 35) = 11.52, p = .00, and
revealed that these three variables combined predicted almost 50% of the variance in
the cognitive efficiency composite score, (Adjusted R2 = .45). Specifically, dialysis
duration prior to transplantation, (f3 = .31, p = .02), and WRAT-3 reading, (fi = .46, p =
.00), contributed a significant portion of the variance in the cognitive efficiency composite
score, while the contribution of months since transplant was not statistically significant.
Dialysis duration prior to transplant and WRAT-3 reading combined predicted just over
40% of the variance in the cognitive efficiency composite score (F? = .41).
The results of the statistical analyses pointed to the important relationship
between specific medical and demographic variables and cognitive functioning in this
relatively small sample of renal transplant recipients.
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VI. DISCUSSION
The present investigation examined the effect of chronic low dose prednisone on
neuropsychological functioning in renal transplant recipients. Specifically, post-renal
transplant recipients enrolled in a SA or a CS protocol were compared with regard to
their cognitive performances in the domains of declarative memory, simple attention,
complex attention, and processing speed.
With regard to group-wise comparisons, based on the literature reviewed, it was
predicted that participants in the SA group would significantly outperform participants in
the CS group with regard to the domains of declarative memory and complex attention.
No such differences were predicted for the domains of simple attention or processing
speed. Contrary to the predictions, there were no reliable group differences on the
domains of declarative memory or complex attention. Moreover, participants in the CS
group significantly outperformed those in the SA group with regard to the domain of
simple attention. However, this difference was not apparent after including months since
transplant as a covariate. As predicted, there were no significant group differences with
regard to the domain of processing speed.
With regard to group-wise differences on specific tests, after controlling for
multiple comparisons, there were no reliable group differences on any test. Before
controlling for multiple comparisons, participants in the CS group performed significantly
better than those in the SA group on the following test scores: TMTA (time), letternumber sequencing, stroop colour-word (time), and digit span backward. Likewise,
before controlling for multiple comparisons, participants in the SA group significantly
outperformed those in the CS group with regard to recognition discriminability on a
verbal list-learning test.
With regard to the first hypothesis regarding the effect of low-dose, chronic
prednisone on declarative memory, the results of the present investigation were not
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generally in accordance with that of the literature reviewed (Brown et al., 2004; Keenan
et al., 1996; Newcomer et al., 1994). There were no significant group differences with
regard to the declarative memory composite score, or on the specific test scores that
comprised this composite score (RAVLT-Total words trials 1-5, 20 min delayed recall
scores, and Logical memory I and II subtests). There are several differences between
the current study and those abovementioned that likely account for the discrepant
findings. First, the studies by Brown and colleagues and Keenan and colleagues
examined declarative memory in relation to moderate to high doses of prednisone. In
both of those studies participants were maintained on a mean dose of 17 mg of
prednisone daily, compared to the current study in which participants were maintained
on an average dose of 4.4 mg of prednisone daily. Second, Newcomer and colleagues
used a different corticosteroid (dexamethasone), an exogenous corticosteroid with a
potency 4-5 times that of prednisone and a longer duration of action (Longui, 2007).
Finally, whereas the current investigation used a control group of individuals matched
with regard to the primary disease (i.e., kidney disease), the study by Keenan and
colleagues used a control group comprised of individuals with various, rheumatic
diseases. It is possible that the heterogeneous nature of their sample may have
contributed to their significant results. Similarly, the study by Brown and colleagues
compared the cognitive performance of their steroid treated participants to that of
healthy controls.
Interestingly, the current study revealed that, before correcting for multiple
comparisons, the performance of the SA group with regard to the recognition
discriminability score was significantly better than that of the CS group. This finding is in
accordance with the study by Keenan et al. (1996) in which prednisone treated patients
performed more poorly than controls on the recognition discriminability score from the
California Verbal Learning Test. Unfortunately, due to the non-normal distribution of this
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score in the current study, the finding could not be further examined by inclusion of a
covariate. Moreover, it is important to note that this difference was not significant after
controlling for multiple comparisons suggesting that it needs to be replicated with a
larger sample to determine its legitimacy.
With regard to the predictions concerning the effect of low-dose, chronic
prednisone on complex attention, the findings of the present investigation were not in
accordance with the reviewed literature that suggested an adverse impact of moderate
to high doses of exogenous GCs on aspects of complex attention such as working
memory, conceptual set-shifting and inhibition (Brown et al., 2004; Lupien, Gillin, &
Hauger, 1999; Young et al., 1999). There were several differences between the current
study and the investigations reviewed that may account for the divergent results. First,
two out of three of the studies reviewed used a different corticosteroid (i.e.,
hydrocortisone), and examined cognitive functioning over days of administration of this
drug (in both studies hydrocortisone was administered for 10 days). Second, there were
differences, from the present study, in the neuropsychological measures used to
evaluate complex attention. Young and colleagues utilized subtests from the Cambridge
Neuropsychological Test Automated Battery, while Lupien and colleagues used an
experimental measure of working memory. Finally, both of these studies examined
cognitive functioning in groups of young healthy males as opposed to a clinical sample.
While the investigation of Brown and colleagues was similar to the current study in their
use of a clinical population and prednisone therapy, they, like the others, examined
cognitive functioning in relation to moderate to high doses of prednisone. Moreover,
their control group consisted of healthy individuals as opposed to clinical controls.
With regard to the fourth hypothesis regarding group differences on the domains
of simple attention and processing speed, as predicted, there were no significant group
differences on the processing speed domain. Furthermore, there were no group-wise
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differences on specific tests from this domain. In terms of the simple attention domain,
contrary to our hypothesis, participants in the CS group appeared to outperform those in
the SA group. However, this difference was not present after including months since
transplant as a covariate.
Contrary to expectations, there were no reliable differences between the CS and
SA groups with regard to the cognitive test scores. One possible explanation of this
result concerns the effect of exogenous GCs on the HPA axis. Evidence from animal
investigations suggests that the relative occupancy of MRs and GRs in the brain partly
determines cognitive efficiency in rats. When the ratio of MR/GR occupancy is low (as in
the case of low circulating GCs, or treatment with excessive exogenous GCs) cognitive
functioning is hampered. Conversely, cognitive functioning is optimal when the MR/GR
occupancy is high (as in the case of moderate doses of exogenous GCs) (Conrad et al.,
1997; Oitzl & DeKloet, 1992; Sandi & Rose, 1997). Investigations with humans have
subsequently reiterated the ability of GCs to modulate aspects of cognitive functioning
(memory) and have lent indirect support to the mechanism of action being via the
differential activation of MRs and GRs (Lupien et al., 2002a; Lupien et al., 2002b). In the
context of the present investigation, a tentative hypothesis would be that a low dose of
exogenous prednisone is not detrimental to cognitive functioning because it does not
result in the necessary degree of activation of GR receptors to alter the ratio of MR/GR
occupancy. This hypothesis likely oversimplifies the relationship being examined as the
question of optimality in terms of levels of circulating GCs is influenced by several
factors including genetics, actual stress exposure, and the time of day (Herbert et al.,
2006).
A second viable and somewhat more tenable explanation for the finding of the
lack of reliable group differences has to do with the influence of specific demographic
and clinical variables on cognitive functioning in this study. In the present study, months
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since transplant, years of education, and WRAT-3 reading all exhibited moderate
positive correlations with at least half, and in some cases (i.e., WRAT-3 reading), all of
the cognitive composite scores. Participants in the CS group exhibited relatively greater
scores on all of these variables than participants in the SA group (i.e., greater time since
transplant, more years of education, and higher reading scores). Therefore, it is
possible that it was the marginal differences with regard to these demographic or clinical
variables that led to the lack of reliable group differences with regard to the cognitive
tests scores.
The second main goal of this investigation was to examine the relationship
between age, prednisone duration, and prednisone dosage for participants in the CS
group. In accordance with the reviewed literature, it was predicted that age and
prednisone duration would account for a significant portion of the variance in the
declarative memory score. Prednisone dose was not expected to significantly predict
the declarative memory score in our sample because all the patients in the CS group
were maintained within a relatively narrow band of dosing (i.e., 2.5 - 7.5 mg/day).
Contrary to the predictions, an initial examination of the data indicated that age
was not significantly correlated with the declarative memory score for participants in the
CS group. Furthermore, although prednisone duration was significantly correlated with
the declarative memory score, it was also strongly correlated with months since
transplant. It was not included as an independent variable in the regression analysis
because the interpretation of the results of such a regression would be confounded by its
strong relationship to months since transplant. The results of preliminary analyses
suggested that dialysis duration prior to transplant, and prednisone dose would be the
best independent variables for regression analyses.
A simple linear regression of dialysis duration prior to transplant on the
declarative memory composite score for participants in the CS group was significant and
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revealed that this variable accounted for almost 20% of the variance in the declarative
memory composite score. After controlling for months since transplant, the memory
difference between patients receiving 2.5 mg or 5 mg of prednisone was not statistically
significant but exhibited a strong trend towards significance. Prednisone dose predicted
approximately 26% of the variance in the declarative memory composite score. Patients
maintained on 5 mg of prednisone exhibited relatively poorer memory scores relative to
patients maintained on 2.5 mg. When an influential data point of 7.5 mg was included
the model appeared to be non-linear. Under these conditions prednisone dose
accounted for a significant portion of the variance in the declarative memory composite
score.
The finding that age was not significantly associated with the declarative memory
composite score for patients maintained on prednisone was unexpected based on the
literature reviewed. Keenan et al., (1996) found that increasing age was significantly
associated with poorer memory for patients receiving prednisone for less than 3 years.
More generally, the failure in the present study to find any significant associations
between age and any of the cognitive composite scores for the entire sample of posttransplant patients was quite surprising. Investigations examining groups of post-renal
transplant recipients have demonstrated a significant association between increasing
age and poorer neuropsychological performance, particularly in the domains of learning
and memory, and attention, concentration and processing speed (Griva et al., 2006;
Griva et al., 2004). One possible explanation of the discrepancy in the present findings
from that of others is that the studies reviewed included older participants, while patients
greater than 60 years of age were excluded in the current investigation. For example,
Keenan and colleagues included patients between the ages of 55 and 73. Moreover,
patients in their sample were exposed to a higher mean dose of prednisone. Another
potential explanation of the failure to find an association between age and cognition may
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be due to the small sample size of transplant recipients enrolled (A/= 39) in the current
study. By comparison, Griva and colleagues acquired a sample size of 117 post-renal
transplant recipients (Griva et al., 2004).
In contrast to the expected findings, the results of the present investigation
suggest that even low doses of prednisone predict a noteworthy proportion of variance in
predicting declarative memory. Perhaps more importantly, even within such a narrow
band of dosing (2.5 - 5 mg/daily) one can discern differences in relative memory
efficiency. Patients receiving 2.5 mg of prednisone exhibited a score on the declarative
memory composite of approximately 56-T, while those receiving 5 mg of the drug
exhibited a score of roughly 47-T. There are only a few other investigations that have
examined the effect of prednisone dose on declarative memory in post-renal transplant
recipients (Bermond et al., 2005; Monastero et al., 2004). Bermond et al., (2005)
demonstrated a negative effect of prednisone doses between 10 and 27 mg on the
delayed recall of auditory-verbal information, while Monastero and colleagues
demonstrated that patients receiving approximately 11 mg of prednisone daily were
more impaired with regard to some domains of cognitive functioning than those receiving
approximately 2 mg daily (unimpaired), although it was unclear on which specific
cognitive domains the differences occurred. The findings presented in the current study
suggest that even low doses of prednisone may have an adverse impact on at least
some aspects of cognitive functioning (i.e., declarative memory) but require replication
with larger sample sizes.
The significant association between duration of dialysis prior to transplantation
and post-transplant neurocognition was also unexpected. There are only a few
investigations in the transplantation literature that have examined this association. Griva
et al. (2006) found a significant inverse association between improvement on a
psychomotor task and time spent on dialysis. Gelb and colleagues failed to find any
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significant associations between duration of dialysis and measures of neurocognition in
their sample of post-renal transplant recipients (Gelb et al., 2007). While Gelb and
colleagues examined renal transplant recipients who had received dialysis for a mean of
approximately 2.6 years prior to transplant, patients in the current study had received
dialysis for a mean of 4 years prior to transplant. Moreover, while the majority of
patients in the current sample (SA, 64%; CS, 70%) were maintained on HD prior to
transplant, it is unclear what the relative composition of dialysis modalities was in that
study. Both of these factors may explain the divergent results of the two investigations.
However, given the literature that demonstrates a significant adverse effect of HD on
aspects of neurocognition (Pereira et al., 2007; Pliskin et al., 1996; Umans & Pliskin,
1998) and the finding that HD is also associated with an increased risk for
cardiovascular disease, sub-clinical white matter disease, and anemia all of which have,
by themselves, been associated with cognitive impairment, the finding of an association
between greater dialysis duration prior to transplant and worse post-transplant cognitive
efficiency is not entirely surprising. The findings of the present investigation suggest that
further exploration of this relationship in post-renal transplant recipients is warranted.
Another finding from the current study that is of interest is the relationship of
months since transplant to neurocognition. Gelb et al., (2007) failed to find any
significant associations between time since transplant and measures of learning and
memory, or attention, concentration and processing speed. By contrast, in the current
investigation moderate correlations were found in the positive direction between months
since transplant, and the composite domains of simple and complex attention for the
entire sample. The discrepancy in the findings of the current study from those of Gelb
and colleagues with regard to the domain of attention and concentration may be due to
the differences in cognitive tests that were utilized. In comparison to their study, the
current included auditory span tests and an experimental version of an auditory working
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memory test to assess attention. More generally, the results of the current analysis, with
regard to months since transplant were consistent with their findings and indicated that it
did not predict a significant proportion of variance in general cognitive efficiency for the
entire sample. Moreover, although at first blush time since transplant appeared to
exhibit a moderately positive association with the declarative memory composite score
for participants in the CS group, after controlling for its strong association with
prednisone dose, it predicted only approximately 6% of the variance in the declarative
memory score.
Clinical Implications
Treatment with low dose, chronic prednisone post-renal transplantation does not
appear to exacerbate cognitive dysfunction beyond the level that can be attributed to
renal-transplantation itself. In the current study, participants in the SA and CS protocols
performed similarly with regard to the domains of declarative memory, simple attention,
complex attention, and processing speed. In comparison to age-corrected normative
data, participants in both groups performed in the low-average to average range across
tests. This finding is in accordance with that of other investigations (Griva et al., 2004;
Griva et al., 2006). This is undoubtedly positive news for recipients of renal
transplantation, and solid organ transplantation in general, as many of these individuals
are enrolled in steroid maintenance protocols.
The current study also revealed that participants maintained on 2.5 mg of
prednisone post-transplantation exhibited relatively better memory scores compared to
those maintained on 5 mg of the drug. A somewhat important implication of this finding
is that if participants are enrolled in steroid maintenance protocols they should be
maintained on the lowest possible dose of prednisone possible, as it is possible that
higher doses, even within relatively low dose ranges, are associated with poorer memory
performance. This finding also argues in favour of steroid tapering wherein the initial
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post-transplant dose of prednisone is reduced to the lowest level that will continue to
prevent graft rejection. The importance of this finding is attenuated by the fact that
participants in the SA group failed to exhibit significantly better memory performances
than those in the CS group. Furthermore, given the rather small sample size employed,
there is a need for replication of this finding.
In the current study it was found that the duration of dialysis prior to transplant
predicted a significant portion of the variance in post-transplant declarative memory.
Moreover, exploratory analyses further revealed that it significantly predicted general
cognitive efficiency, post-renal transplantation. Our findings imply that longer periods of
dialysis, and specifically HD, prior to transplant are associated with poorer memory and
cognitive efficiency post-transplantation. This finding reiterates the importance of
exploring alternative regimens of dialysis and using pre-emptive protocols, where
possible, so participants are transplanted directly without ever having to initiate dialysis.
Finally, in the current study it was found that months since transplant was moderately
associated with at least half of the cognitive composite scores for the group as a whole
(i.e., simple attention and complex attention). Furthermore, although it did not contribute
a significant portion of the variance in the declarative memory composite score after
adjusting for prednisone dose, it did exhibit positive associations with declarative
memory for both the CS and SA groups. The findings with regard to time since
transplant point to the possibility that neurocognition post renal transplantation appears
to improve with a greater time since transplant. Although this finding makes intuitive
sense, the results presented here warrant further investigation of the relationship of this
variable to post-transplant neurocognition.
Limitations
There were several significant limitations in the present study. Chief amongst
these was the small sample size utilized that prevented the examination of more intricate
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relationships between variables and also significantly reduced the power of the analyses
that were conducted. As an example, for the regression of dialysis duration on the
declarative memory composite score, the calculated power with a sample size of 17, an
alpha level of .05, and an R2= .193 was approximately 48%. If we had wanted the power
to be closer to 80% on an a priori basis, then the sample size of the CS group would
have had to have been approximately n= 35, a substantially larger sample.
Another obvious limitation of the study is the lack of a group of healthy control
participants to which the performance of the two clinical groups could be compared. The
inclusion of such a group would have enabled finer conclusions to be drawn about the
possible effect of low-dose chronic prednisone on particular tests relative to healthy
controls. It would have also helped to assess the possible clinical significance of
performances on tests for which no age-corrected normative data was available (e.g.,
the auditory version of the N-back test).
Although the current study employed relatively rigorous inclusionary and
exclusionary criteria it was not possible to match participants in the SA and CS groups
with regard to all of the clinical and demographic variables. This somewhat limited the
internal validity of the study, as group differences in cognitive functioning may have been
attributable to these confounding variables. Clearly, a more definitive manner to study
the phenomena under observation would be through the use of a longitudinal design.
Such a design would also enable one to draw more definitive conclusions about the
effects of such variables as duration of dialysis, and time since transplant on cognitive
functioning.
In the current study participants with a wide variety of problems were excluded
including clinically significant psychological symptoms, evidence of uncontrolled
diabetes, and those maintained on cyclosporine just to name a few. The rigorous
exclusionary criteria likely limit the generalizability of our results to some extent as most
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clinical populations of renal transplant recipients likely include some individuals in these
categories.
Although the primary researcher was able to equate both post-renal transplant
groups with regard to a variety of variables such as medications, age, and estimated
level of current kidney function, it was not possible to include various markers of
immunological status such as level of panel reactive antibodies at transplant because
this information was unavailable. Furthermore, due to the cross-sectional nature of the
investigation, there may have been group differences in terms of pre-transplant variables
that the analyses were unable to address.
There are obvious merits to the examination of the effect of low dose steroids
using cumulative dosing strategies wherein a patient's exposure to the drug over a long
period of time is taken into consideration. Unfortunately, it was not possible to examine
this phenomenon in the current study because the information was unavailable.
One of the secondary objectives in the current study was to attempt to test
participants in the afternoon so we could more clearly explicate the effect of exogenous
corticosteroid therapy on cognition. This was done in accordance with the literature that
has demonstrated a consistent temporal variation in endogenous Cortisol, with the trough
occurring during the afternoon in humans (Lupien et al., 2002b; Newcomer et al., 1994).
However, because the renal-transplant clinics were typically held in the morning it was
no possible to meet this objective. All of the patients in the current investigation were
tested in the morning.
Unfortunately it was not possible to examine the relationship between
biochemical measures and cognitive functioning because the lab values could not
always be collected on the day of testing. For this same reason, average values of GFR
had to be averaged to obtain reliable estimates of kidney function.
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Although the findings presented here suggest a relationship between dialysis
duration prior to transplant and post-transplant declarative memory it was not possible to
examine the contribution of dialysis compliance as a variable moderating this
relationship. Furthermore, although patients in the CS group were maintained on
prednisone, it was not possible to examine the contribution of medication compliance in
an examination of reliable group differences between the CS and SA group.
Future Investigations
The limitations listed above suggest several possible avenues of research for
future studies. First, in light of the low statistical power in the present investigation, it
would certainly be worthwhile to replicate the current findings with a larger sample size.
Given the difficulty in obtaining participants from this patient population this may be
optimally achieved through a large multi-center investigation. It is also important that a
control group of healthy, age-matched participants be included for comparative
purposes. Second, a longitudinal investigation would be the most definitive manner in
which to examine the effect of prednisone on cognition as participants could serve as
their own controls. Moreover, this would enable one to more carefully examine the rate
and trajectory of detrimental cognitive changes that occur as a result of chronic pretransplant HD and more clearly delineate the rate and extent of the positive cognitive
changes that appear to occur as a result of renal transplantation. Third, it may be
interesting to replicate the current study with an older sample of renal transplant
recipients. Given the evidence that at least some groups of elderly patients exhibit
increased endogenous Cortisol levels, they may be more sensitive, in terms of cognitive
functioning, to even low levels of exogenous GCs (Lupien et al., 1996). Fourth, it would
be worthwhile to include additional variables such as dialysis and medication adherence
and markers of immunological status in future investigations examining similar
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phenomena. Finally, future investigations should continue to consider the importance of
the diurnal variation in endogenous Cortisol when designing paradigms.
In conclusion, the findings presented here suggest that post-renal transplant
recipients maintained on chronic, low-dose prednisone are not more cognitively
compromised than those who are not. However, the possibility was raised that
prednisone dose post-transplant does appear to have a relationship with memory
functioning as patients maintained on relatively higher doses of the drug (i.e., 5 mg)
exhibited relatively poorer memory performances than those maintained on lower doses
(i.e., 2.5 mg). Moreover, the results suggest that further exploration into the nature of
the relationship between chronic prednisone therapy and neurocognition in this patient
population is warranted.
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Table 1
National Kidney Foundation Kidney Disease Outcomes Initiative Classification (K/DOQI)
of Stages of Chronic Kidney Disease

Stage

Description

GFR (mL/min/1.73m2 bsa)

1

Kidney damage with normal or increased GFR

>90

2

Kidney damage with mildly decreased GFR

60-89

3

Moderately decreased GFR

30-59

4

Severely decreased GFR

15-29

5

Kidney failure

<15 (or dialysis)

Note. GFR = Glomerular Filtration Rate.
Note. Information for table adapted from K/DOQI Guidelines 2002.
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Table 2
Description of all the tests administered as part of the protocol

Brief Symptom Inventory (BSI) (Derogatis, 1983)
The BSI is a 53 item psychiatric screening tool frequently utilized in clinical settings.
This self-report instrument generates 9 primary symptom dimensions and three global
indices, of which one is the global severity index.
Wide Range Achievement Test- 3ra Edition (Wilkinson, 1993)- (WRAT-3) Reading
Subtest.
The reading subtest requires the subject to pronounce words out of context, and may
require them to pronounce letters out of context. The total score is the number of words
correctly pronounced.
Wechsler Memory Scale- 3ra Edition, (WMS-III) Logical Memory I and II (LMI and LMII)
(Wechsler, 1997)
This is a test of declarative memory. The first section (LMI) requires the subject to listen
to a story read aloud and immediately recall as much as he/she can remember. This
procedure is repeated for a second story. After a 20 to 25 minute delay, during which
other tests are administered, the subject is administered LMII during which he/she must
recall as much as he/she can remember from the two stories. The subject is then
administered a forced choice recognition test and must choose from two elements, one
of which was in the initial stories. The score for the immediate and delayed recall trials
is the number of story elements correctly recalled, whereas the score for recognition is
the number of elements correctly identified.
Rey Auditory Verbal Learning Test, (RAVLT) (Schmidt, 1996)
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This is a test of declarative memory. The subject is read aloud a list of 15 words, and
must repeat back as many as he/she can remember. This list (list A) is administered
four more times and each time the subject repeats back what can be remembered. The
subject is then read a different list of words (list B), and must recall as many words from
this new list as he/she can remember. After this, the subject is asked to recall as many
words as possible from list A (short-delayed recall). After a 20-25 minute delay, the
subject is asked to recall all the words he/she can remember from list A (long-delayed
recall). Finally a list is presented to the subject containing words from list A, list B, and
several foils. The subject must identify words from list A and list B (recognition). Total
score for the recall sections is the number of words correctly recalled. Total score for
recognition is the number of words correctly recognized. A discriminability score is
calculated that represents the ratio of words from list A correctly recognized relative to
foil words that are endorsed.
Trail Making Test Part A, (TMTA) (Reitan, 1985)
This is a test of simple attention. The subject is asked to draw a line connecting a series
of numbers in numerical order as quickly as possible. Total score is time to complete.
Number of errors is also recorded.
Wechsler Adult Intelligence Scale- 3m Edition, (WAIS-III)- Digit Span Subtest (Wechsler,
1997)
This is a test of attention. The subject is read aloud a series of numbers of progressively
longer lengths. After each series is read, the subject must recall the series in the correct
order. The test is discontinued either after all items are administered, or after the subject
commits errors on all three trials of an item. The subject is then read aloud a series of
numbers of progressively longer lengths in reverse numerical order, after which he/she
is asked to recall as many as possible. The total score is the number of series correctly
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recalled.
Stroop Colour Word Test- Victoria

Version (Regard, 1981)

This is a test of inhibition and disinhibition. Three cards are presented to the participant:
D, W, and C. With card D the participant must name as quickly as possible the colour of
24 dots printed in blue, green, red, or yellow. Each colour is used six times, and the four
colours are arranged in pseudo-random order within the array, each colour appearing
once in each row. Card W is similar to D except the dots are replaced by common
words (when, hard, and over), printed in lower-case letters. The participant must name
the colour of the words but ignore their content. Card C is similar to cards D and W
except the coloured stimuli are the colour names "blue, green, red and yellow" printed in
lower case letters, so the print colour never corresponds with the colour name.
Participants are required to name the colours in which the words are printed. The total
score is the time to completion for each card, and the total number of errors.
WAIS-III- Letter-Number Sequencing Subtest (Wechsler, 1997)
This is a test of working memory capacity. The subject is read aloud a series of
numbers and letters in mixed series. The subject must recall each series after
presentation, but produce numbers first in ascending order followed by letters in
alphabetical order. The series get longer as the test progresses. The test is
discontinued either after administration of all the items, or after the subject commits
errors on all three trials of any item. The total score is the number of series correctly
recalled.

Trail Making Test Part B, (TMTB) (Reitan, 1985)
This test is thought to assess cognitive set-shifting. It is a paper and pencil task that
requires the subject to connect a series of numbers and letters, alternating between the
two. The letters must be connected in alphabetical order and the numbers in ascending
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order. For example, the subject is asked to start at the number 1 and draw a line to A
then to 2 then to B, 3, C etc. until they reach the circle, marked end. The total score is
the time to completion. Total number of errors is recorded.
Auditory N-Back Test (adapted from Lengenfelder et al., 2003)
The N-back test is thought to be a sensitive measure of working memory capacity
(Saykin, Johnson, & Flashman, 1999; McAllister, Saykn, & Flashman, 1999). The
auditory version requires the subject to listen to a string of consonant letters presented
auditorily every 3 seconds via cassette tape. Three conditions are presented: 0-back, 1back, and 2-back. There are two blocks of five trials for each condition. In the 0-back
condition, the subject is asked to decide whether a certain letter matches a single target
letter that is previously specified by tapping on the table when the target letter is heard.
In the 1-back condition the participant must decide whether a presented letter matches
the one just preceding it by tapping on the table. The 2-back condition requires the
participant to indicate via table tap whether a presented letter matches one 2-back in the
sequence. The score is the total number of errors made in each condition.
WAIS-III, Digit-Symbol Coding Subtest (Wechsler, 1997)
This is a test of processing speed and requires the subject to complete a series of
boxes, by filling in the symbol that corresponds with the number in the top half of the box
as quickly as possible (the numbers are in scrambled order). They use a grid presented
at the top of the page. The total score is the time to completion.
WMS-III, Spatial Span Subtest (Wechsler, 1997)
This is a test of attention and non-verbal working memory. The subject is presented with
a form board containing a number of coloured blocks. The examiner outlines specific
patterns by touching various blocks. After this, the subject is required to tap the same
blocks. The series again, get progressively longer as the test goes on. Following this
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the subject is required to tap the blocks in the reverse order of that demonstrated by the
examiner. The subtest is discontinued when the subject commits errors on all three
trials of an item. The total score is the number of series correctly recalled for both
forward and backward procedures.
WAIS-III, Symbol Search Subtest (Wechsler, 1997)
This is a test of processing speed and visual scanning. The subject is required to
indicate whether either of two symbols presented on the right side of the page match a
series of symbols on the left side. They are required to complete the test as quickly as
they can without skipping any items. Total time is 120 seconds, and the total score is
the number correct minus the number incorrect.
CAGE4
This is a four item screening measure for alcohol abuse. The questions assess whether
the subject has attempted to cut-down on his/her alcohol consumption unsuccessfully,
whether he/she gets annoyed when reminded of his/her habit, whether he/she feels
guilty after he/she has drunk, and whether the subject has used alcohol as an eye
opener.
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Table 3
Tests comprising each composite category
Declarative Memory
-WMS-III Logical Memory I (total correct)
-WMS-III Logical Memory II (total correct)
-RAVLT (total words trials 1-5)
-RAVLT (20-minute delayed recall)
-RAVLT (discriminability)
Complex Attention
-TMTB (time to completion)
-TMTB (errors)
-Stroop Colour Word Test (colour-word trial time to completion)
-Stroop Colour Word Test (colour-word trial errors)
-Auditory N-Back Test (1-back total errors)
-Auditory N-Back Test (2-back condition total errors)
-WAIS-IIII Letter-Number Sequencing (total correct)
-WAIS-III Digit Span backward (total correct)
-WMS-III Spatial Span backward (total correct)
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Simple Attention
-WAIS-III Digit Span forward (total correct)
-WMS-III Spatial Span forward (total correct)
-Auditory N-Back Test (0-back condition total errors)
-TMTA (time to completion)
Processing Speed
-WAIS-IIII Digit-Symbol Coding subtest (total correct)
-WAIS-III Symbol Search subtest (correct-incorrect)
-Stroop Colour Word Test (colour naming trial time to completion)
-Stroop Colour Word Test (word reading trial time to completion)

Note. Text in bold represents the Cognitive Composite domain.
WMS-III = Wechsler Memory Scale 3rd Edition
WAIS-III = Wechsler Adult Intelligence Scale 3rd Edition
RAVLT = Rey Auditory Verbal Learning Test
TMTB = Trail Making Test Part B
TMTA = Trail Making Test Part A
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Table 4
Descriptive information and group-wise comparisons for demographic and clinical variables for participants
in the steroid avoidance (SA) and chronic steroid (CS) groups

Variable

SA (n=22)

CS(n=17)

Test Statistic

Significance (p)

Age (months)

537 (233-728)

504 (256-684)

t=.82

.42

Gender (male/female)

16/6(72.7%/27.3%)

8/9(47.1%/52.9)

X^=2.67

.10

Handedness (right/left)

20/2 (90.9%/9.1%)

15/2 (88.2%/11.8%)

X^= .07

.79 (1.0)

European American

10(45.5%)

4 (23.5%)

^=2.00

.16 (.19)

African American

10(45.5%)

12(70.6%)

Xf=2A6

.12

Asian American

1 (4.5%)

0

Other

1 (4.5%)

1 (5.9%)

Hypertension

15(68.2%)

7(41.2%)

y?= 2.84

.09

Diabetes

1 (4.5%)

3(17.6%)

Hypertension+Diabetes

5 (22.7%)

5 (29.4%)

Other

1(4.5%)

2(11.8%)

Cadaveric

15(68.2%)

12 (70.6%)

>?= .03

.87

Living related donor

7(31.8%)

4 (23.5%)

Living unrelated donor

0

1(5.9%)

X^= .21

.65

>?= .84

.36

Ethnicity

ESRD Etiology

Type of Transplant

Type of Dialysis Prior to Transplant
None

2 (9.1%)

1(5.9%)

Hemodialysis

14(63.6%)

12 (70.6%)

Peritoneal dialysis

4(18.2%)

3(17.6%)

Both

2(9.1%)

1 (5.9%)

Antihypertensive Treatment
Beta Blockers

11(50%)

11(64.7%)
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Other antihypertensives

10 (45%)

13 (76%)

Years of education

12.8(10-18)

13.9(12-18)

f=2.6

.01

GFR(ml/min. 1.73m2)

67.4(40-105.4)

64.1(40-107.7)

f=.53

.60

Systolic blood pressure (mm Hg) 132.1 (104-165)

135.2 (105-155)

f=.90

.33

Diastolic blood pressure (mm Hg) 80.3 (70-98)

77.9 (64-97)

f=.72

.48

Months since transplant

27.4 (6-70)

f=1.64

.11

50.7 (0-104)

U= 156.0

.39

mycophenolate mofetil dose/day (mg)1765 (1080-3000)1374.7 (1000-2000)*

U=85.0

.00

tacrolimus dose/day (mg) 9.3 (1.5-16)

7.3 (2-18)

U=79.0

.41

WRAT-3 Reading Score

87.8 (60-111)

92.0 (64-107)

L/= 151.0

.32

BSI(GSI)

50.7(33-65)

51.3(33-60)

f=.25

.81

19.8 (6-51)

Duration of Dialysis (months) 47 (0-170)

Note. For continuous variables numbers in parentheses are ranges.
Numbers in italics are values associated with Fisher's exact test.
t = one-tailed independent samples t-statistic.
U = one-tailed independent samples Mann-Whitney U statistic.
X^= Chi-squared statistic.
GFR = Glomerular Filtration Rate.
WRAT-3 Reading Score = Wide Range Achievement Test 3rd Edition, Reading Subtest Standard Score.
BSI (GSI) = Brief Symptom Inventory (Global Severity Index) T-score.
mm Hg = millimeters of mercury.
*p<.05, after adjusting for multiple comparisons.
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Table 5
Age-adjusted scaled scores and age-adjusted t-scores on neuropsychological tests for
participants in the steroid avoidance and chronic steroid groups

Test Score

Steroid Avoidance (n=22)

Chronic Steroid (n=17)

Digit Span

8.4 (2.3)

9.6 (2.9)

Letter-Number Sequencing

8.5 (2.6)

10.0(2.1)

Digit Symbol Coding

8.7(3.1)

9.7 (3.3)

Symbol Search

9.1 (2.9)

9.8 (3.3)

Logical Memory I

9.1 (2.1)

9.4 (2.8)

Logical Memory II

10.2(2.4)

10.7(2.7)

Spatial Span

9.2 (2.6)

9.3 (2.6)

RAVLT (Total 1-5)

49.3(14.2)

50.4(12.7)

RAVLT (Delayed)

49.8(11.8)

50.6(12.1)

Stroop Dots (time)

51.9(11.1)

50.2(10.8)

Stroop Words (time)

49.3(11.0)

47.6 (11.3)

Stroop Colour-Word (time)

47.4 (11.4)

51.9(6.5)

TMTA (time)

49.7 (9.4)

53.5 (7.7)

TMTB (time)

51.6(9.5)

54.5 (6.7)

Note. Numbers in parentheses are standard deviations.
RAVLT (Total 1-5) = Rey Auditory Verbal Learning Test total words trials 1-5.
RAVLT (Delayed) = Rey Auditory Verbal Learning Test delayed recall.
TMTA (time) = Trail Making Test Part A time to completion in seconds.
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TMTB (time) = Trail Making Test Part B time to completion in seconds.

Scores for Digit Span, Letter-Number Sequencing, Digit Symbol Coding, Symbol Search,
Logical Memory I, Spatial Span, and Logical Memory II, are scaled scores each with a
mean of 10 and a standard deviation of 3.

Scores for RAVLT (Total 1-5), RAVLT (Delayed), Stroop Dots (time), Stroop Words
(time), Stroop Colour-Word (time), TMTA (time), and TMTB (time), are t-scores each
with a mean of 50 and a standard deviation of 10.
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Table 6
Published normative data used to derive

i-based scaled scores and t-scores

Normative Data Set

Test Scores

WAIS-III

Digits Span

Administration Manual (Wechsler, 1997)

Letter-Number Sequencing
Digit Symbol Coding
Symbol Search

WMS-III

Logical Memory I

Administration Manual (Wechsler, 1997)

Logical Memory II
Spatial Span

Geffen, Moar, O'Hanlon, Clark & Geffen

RAVLT (Total 1-5)

(as cited in Mitrushina, Boone, & D'Elia, 999)

RAVLT (Delayed)

Tombaugh, Rees & Mclntyre (as cited in

TMTA (time)

Spreen & Strauss, 1998)

TMTB (time)

Bullock, Brulot & Strauss (as cited in

Stroop Dots (time)

Spreen & Strauss, 1998)

Stroop Words (time)
Stroop Colour-Word (time)
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Note. WAIS-III = Wechsler Adult Intelligence Scale- 3rd Edition.
WMS-III = Wechsler Memory Scale- 3rd Edition.
RAVLT (Total 1-5) = Rey Auditory Verbal Learning Test total words trials 1-5.
RAVLT (Delayed) = Rey Auditory Verbal Learning Test delayed recall.
TMTA (time) = Trail Making Test Part A time to completion in seconds.
TMTB (time) = Trail Making Test Part B time to completion in seconds.
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Table 7
Spearman's correlations for each of the continuous demographic and medical variables with the
four cognitive composite scores

Variable

DECOM

SIMAT

COMAT

PS

Age (months)

.19 (.24)

. 14 (.88)

-.20 (.23)

-.22 (.19)

Education (years)

.30 (.06)

.21 (.20)

.36 (.02)

.19 (.23)

WRAT-3 Reading

.49 (.01)

.31 (.05)

.55 (.00)*

.31 (.02)

Systolic Blood Pressure

-.13 (.43)

.11 (.51)

-.15 (.36)

.01 (.94)

Diastolic Blood Pressure

.05 (.77)

.14 (.38)

.02(.92)

.02(.90)

MMF dose per day (mg)

.03 (.86)

-.32 (.05)

-.17 (.31)

-.06 (.70)

Duration of Dialysis (months)

-.37 (.02)

-.16 (.34)

-.40 (.01)

-.57 (.00)*

Months since Transplant

.25 (.12)

.42 (.01)

.43 (.01)

.27 (.09)

GFR

.08 (.64)

.02 (.86)

.05 (.75)

.03 (.86)

BSI (GSI) score

-.15 (.36)

-.07 (.68)

-.07 (.67)

-.23 (.15)

tacrolimus dose per day (mg)

-.12 (.54)

-.21 (.27)

-.28 (.14)

-.24 (.21)

Note. The italicized number represents the value of eta and the corresponding p-value.
DECOM = Declarative memory composite score.
SIMAT = Simple attention composite score.
COMAT = Complex attention composite score.
PS = Processing speed composite score.
GFR = Glomerular Filtration Rate (ml/min/1.73m2).
BSI (GSI) = Brief Symptom Inventory (General Severity Index) raw score.
WRAT-3 Reading = Wide Range Achievement Test- 3rd Edition, reading subtest raw score.
MMF = mycophenolate mofetil.
Systolic and diastolic blood pressure values are in millimeters of mercury.
*p<.05, after adjustment for multiple correlations.
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Table 8
Z-scores and group-wise comparisons for each of the tests used to form the cognitive
composite scores for participants in the steroid avoidance (SA) and chronic steroid (CS)
groups

Domain/Test Score

SA (n=22)

CS (n=17) Test Statistic Significance (p)

Declarative Memory

-.02(.76)

.03(.86)

f=.19

.42

WMS- LMI

-.06(.93)

.08(1.1)

t=A2

.34

WMS-LMII

-.08(.94)

.10(1.1)

f=.56

.29

RAVLT(1-5)

-.14(1.0)

.18(.92)

t=.97

.17

RAVLT Long Delay

-.06(1.0)

.07(.99)

t=A0

.34

Discriminability

.22(.87)

-.29(1.1)

U=-\25

.04

Simple Attention

-.18(.54)

.23(.45)

f=2.52

.02*

Digit Span Forward

-.16(.99)

.21(1.0)

t=1.2

.12

Spatial Span Forward

-.20(1.0)

.26(.90)

U= 150

.15

TMT Part A

-.23(1.1)

.29(.84)

t= 1.7

.05

0-Back Condition

-.12(1.3)

.16(.00)

(7=178.5

.41

Complex Attention

-.12(.52)

.15(.51)

F=.94

.34

Digit Span Backward

-.25(.72)

.33(1.2)

f=1.9

.04

Spatial Span Backward

.18(.97)

-.24(1.0)

f = 1.3

.10

Letter Number Sequencing

-.32(.99)

.41 (.87)

t=2A

.01

Stroop Colour-Word

-.23(1.1)

.30(.80)

f=1.7

.04

Stroop Colour-Word Errors

-.06(1.0)

.07(1.0)

L/=164

.26

TMT Part B

-.22(1.0)

.29(.87)

U= 152.5

.17
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TMT Part B Errors

-.05(1.1)

.07(.81)

l>=186

.49

1 -Back Condition

.09(.83)

-.11(1.2)

U= 180

.43

2-Back Condition

-.20(1.0)

.25(.97)

U= 132.5

.06

Processing Speed

-.05(.88)

.06(.77)

0=18

.49

Digit Symbol Coding

-.18(.94)

.23(1.0)

f = 1.3

.10

Symbol Search

-.12(1.1)

.17(.91)

/ = .91

.18

Stroop Dots time

.06(1.0)

-.08(.96)

0=163

.26

Stroop Words time

.05(1.0)

-.07(1.0)

t=.37

.36

Note, t = one-tailed independent samples t-test.
U = Mann-Whitney U test.
F = Results of univariate ANCOVA with years of education as a covariate.
WMS-LMI = Wechsler Memory Scale- Logical Memory I.
WMS-LMII = Wechsler Memory Scale-Logical Memory II.
RAVLT (1-5) = Rey Auditory Verbal Learning Test total words trials 1-5.
RAVLT Long Delay = Rey Auditory Verbal Learning Test 20-minute delayed recall.
Discriminability = Rey Auditory Verbal Learning Test discriminability.
TMT Part A = Trail Making Test part A time to completion in seconds.
TMT Part B = Trail Making Test part B time to completion in seconds.
TMT Part B Errors = Trail Making Test part B total errors.
0-Back Condition = N-back test of working memory 0-back condition.
1-Back Condition = N-back test of working memory 1-back condition.
2-Back Condition = N- back test of working memory 2-back condition.
*p<.05, one-tailed for composite domain comparisons.
**p<.05, one-tailed after adjustment for multiple comparisons for test scores.
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Table 9
Results of non-parametric correlations between the declarative memory composite score
and the continuous medical and demographic variables for participants in the chronic
steroid group
Variable

DECOM

Significance (p)

Age (months)

.25

.34

Education (years)

.03

.91

WRAT-3 reading

.33

.20

Systolic Blood Pressure (mm Hg)

-.17

.52

Diastolic Blood Pressure (mm Hg)

.22

.40

MMF dose per day (mg)

. 17

.51

Duration of Dialysis (months)

-.44

.07

Months since Transplant

.48

.05

GFR(ml/min/1.73m2)

.10

.72

BSI (GSI)

-.33

.21

Tacrolimus dose per day (mg)

-.40

.14

Note. DECOM = Declarative memory Composite Score.
Coefficients under DECOM represent values of Spearman's rho.
WRAT-3 reading = Wide Range Achievement test 3rd Edition, reading subtest raw score.
BSI (GSI) = Brief Symptom Inventory (General Severity Index) raw score.
Mm Hg = Millimeters of mercury.
MMF = mycophenolate mofetil.

*p<.05.
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Table 10
Kendall tau correlations between the categorical demographic and medical variables and
the declarative memory composite score for participants in the chronic steroid group
Variable

DECOM

Gender

.28

.18

African Americans

-.07

.75

European Americans

.10

.65

Hypertensives

.16

.43

Cadaveric Transplants

.34

.06

Hemodialysis

-.13

.53

Note. N= 17.
DECOM = Declarative memory composite score.
Values under DECOM are values of Kendall's T.

*p<.05.

Significance (p)
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Table 11
Spearman's correlations and the corresponding values of eta-squared between the
continuous medical and demographic variables and dose of prednisone for participants
in the chronic steroid group
Variable

rs (n2)

Age (months)

.26 (.08)

.32 (.54)

Education (years)

.15 (.06)

.57 (.65)

WRAT-3 reading

-.07 (.09)

.79 (.52)

Systolic Blood Pressure (mm Hg)

-.04 (.02)

.87 (.88)

Diastolic Blood Pressure (mm Hg)

-.39 (.23)

.13 (.16)

MMF dose per day (mg)

-.08 (.01)

.78 (.92)

Duration of Dialysis (months)

.22 (.22)

.41 (.18)

Months since Transplant

-.62 (.34)

.01 (.06)

GFR(ml/min/1.73m2)

-.22 (.09)

.41 (.51)

BSI (GSI)

-.02 (.06)

.94 (.66)

tacrolimus dose per day (mg)

.20 (.08)

.50 (.34)

Significance (p)

Note. N= 16 for rs and N= 17 for eta-squared.
Significance values in parentheses represent tests of the significance of
eta-squared.
MMF = mycophenolate mofetil.
WRAT-3 reading = Wide Range Achievement test- 3rd Edition, reading subtest raw
score.

Renal Transplant and Cognition 145
BSI (GSI) = Brief Symptom Inventory (General Severity Index) raw score.
*p<.05 after adjustment for multiple correlations.
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Table 12
Summary of Standard Regression Analysis of declarative memory on duration of dialysis
for participants in the chronic steroid group (N = 16).

Variable

B

SE6

P

Dialysis Duration

-.41

.19

-.49

Note.

*p<.05.

#=.24.
Adjusted P?= .19.

Significance
.04*
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Figure Caption
Figure 1. Mean z-scores for each of the four cognitive composite domains for
participants in the Chronic Steroid (CS) and Steroid Avoidance Groups (SA).

0.4 -mm®®®

CS
SA

Composite domain

Note. DM= Declarative memory composite score.
SA= Simple attention composite score.
CS= Complex attention composite score.
PS= Processing speed composite score.
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Figure Caption
Figure 2. Scatterplot of the non-linear relationship between the declarative memory
composite score (y-axis) and the mean dose of prednisone (x-axis) with the inclusion of
the 7.5 mg data point for participants in the Chronic Steroid Group.
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Figure Caption

Figure 3. Normal probability plot and scatterplot of the standardized residuals for the
regression of duration of dialysis prior to transplant on the declarative memory
composite score.
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Note. DEC0M3= Declarative memory composite score.
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APPENDIX A
List of Common Abbreviations
CKD- Chronic Kidney Disease
HD- Hemodialysis
PD- Peritoneal Dialysis
GFR- Glomerular Filtration Rate
Bsa- Body Surface Area
Kt- Total cleared volume of urea
V- Distribution Volume
t- Total dialysis time
CAPD- Continuous Ambulatory Peritoneal Dialysis
TMTA- Trail Making Test Part A
TMTB- Trail Making Test Part B
WAIS-R- Wechsler Adult Intelligence Scale- Revised
WMS- Wechsler Memory Scale
PASAT- Paced Auditory Serial Addition Test
WMS-III- Wechsler Memory Scale- 3rd Edition
WAIS-III- Wechsler Adult Intelligence Scale- 3rd Edition
SAM- Sympathetic-Adrenal-Medullary axis
HPA- Hypothalamic-Pituitary-Adrenal-Cortical system
MC- Mineralocorticoid
GC- Glucocorticoid
MR- Mineralocorticoid Receptor
GR- Glucocorticoid Receptor
CORT- Corticosterone

ADX- Adrenalectomized
ACTH- Adrenocorticotropic hormone
PSE- Positive Slope Elevated
PSM- Positive Slope Moderate
NS- Negative Slope
WCST- Wisconsin Card Sorting Test
WMS-R- Wechsler Memory Scale- Revised
MRI- Magnetic Resonance Imaging
RAVLT- Rey Auditory Verbal Learning Test
LMI- Logical Memory I
LMII- Logical Memory II
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APPENDIX B
Research Informed Consent Form
Title of Study: The Effect of Chronic Low-dose Prednisone on Neuropsychological
functioning in Renal transplant Recipients
You are being asked to be in a research study of the effects of Prednisone therapy on
memory and thinking at Wayne State University. Please read this form and ask any
questions you may have before agreeing to be in the study.
The study is being conducted by Steven F. McArthur, Ph.D., Department of Psychiatry,
Wayne State University in conjunction with Nikhil S. Koushik, M.A., Doctoral Candidate,
University of Windsor and Anne D. Baird, Ph.D., Associate Professor, University of
Windsor.
Study Purpose:
The purpose of the study is to find out if long-term Prednisone exposure causes
problems with memory and thinking. The estimated number of study participants to be
enrolled at Wayne State University is about 42.
Study Procedures:
If you take part in the study, you will be asked to take part in a variety of paper and
pencil based tasks.
•
•
•
•
•

•

These tasks will consist of a survey relating to current mental health functioning
as well as measures of memory and problem solving.
To be included in the study you will have to answer all the questions on the
survey of mental health functioning. Other information that will be gathered
includes: years of education and handedness.
You may be asked some questions that make you uncomfortable. You may
choose not to answer those specific questions and still participate in the study.
The study will require approximately 2 hours of your involvement and, if possible,
will be coordinated with your regular clinic appointment.
If you complete all the necessary testing you will receive a one-page summary of
your performance at your next clinic appointment. The group results for the
study, but with absolutely no identifying information, will be posted on the
University of Windsor ethics website at:
http://web4.uwindsor.ca/units/researchEthicsBoard/studyresultforms.nsfA/isitorVi
ew?OpenForm
These results will be posted latest by January 31, 2008.

Benefits:
•

The possible benefits to you for taking part in this study are that you will learn
whether you have significant problems with memory or other areas of thinking. If
such a problem is revealed you will receive the appropriate referral for treatment
through your transplant nephrologist. Also, by taking part in this study you will help
your transplant nephrologist better manage your care. Information from this study
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may also reveal that long-term exposure to steroids may result in problems with
memory and problem solving for transplant recipients in general. Furthermore, the
data you provide with regard to memory and problem solving may be used in
subsequent investigations to better understand the long-term impact of Prednisone
therapy.
Risks: There are no known risks at this time to participation in this study.
Compensation:
•
•

•

•

For taking part in this research study, you will be paid twenty dollars ($20.00) for your
time and inconvenience.
If you consent to be enrolled in the study, you will then be administered a few small
paper-and-pencil tasks to further demonstrate your eligibility. These tasks will not
take more than 15 minutes.
These few tasks will be scored by the test administrator on the spot. If your
performance on these measures falls within the specified limits then the rest of the
tasks will be administered and you will be paid twenty dollars ($20.00).
BUT, if your performance on these tasks does not fall within the specified limits, the
administrator will explain the reason for your exclusion and you will be paid ten
dollars ($10.00). In this case the rest of the tests will not be administered, and you
will be free to leave.

Confidentiality:
All information collected about you during the course of this study will be kept
confidential to the extent permitted by law. You will be identified in the research records
by a code name or number. Information that identifies you personally will not be
released without your written permission. However, the study sponsor, the Human
Investigation Committee (HIC) at Wayne State University or federal agencies with
appropriate regulatory oversight, may review your records.
Personal Health Information (PHI) used and disclosed for the purposes of this study is
protected under the federal regulation known as HIPAA (Health Insurance Portability and
Accountability Act). Your study investigator will discuss with you your rights under this
federal regulation and obtain your authorization to allow the research team to access
your PHI.
Voluntary Participation /Withdrawal:
Taking part in this study is voluntary. You may choose not to take part in this study, or if
you decide to take part, you can change your mind later and withdraw from the study.
You are free to not answer any questions or withdraw at any time. Your decision will not
change any present or future relationships with Wayne State University or its affiliates or
other services you are entitled to receive. Your decision to withdraw from the study will
not affect your health care or treatment in the Renal Transplantation Program in any
way. If you choose to withdraw from the study you will not receive any monetary
compensation. The investigator, or the sponsor, may stop your participation in this study
without your consent. While taking part in this study, you will be told of any important
new findings that may change your willingness to continue to take part.
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Questions:
If you have any questions now or in the future, you may contact Steven F. McArthur,
Ph.D., or one of his/her research team members at the following phone number. If you
have questions or concerns about your rights as a research participant, the Chair of the
Human Investigation Committee can be contacted at (313) 577-1628.
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Consent to Participate in a Research Study:
To voluntarily agree to take part in this study, you must sign on the line below. If you
choose to take part in this study, you may withdraw at any time. You are not giving up
any of your legal rights by signing this form. Your signature below indicates that you
have read, or had read to you, this entire consent form, including the risks and benefits,
and have had all of your questions answered. You will be given a copy of this consent
form.

Signature of Participant

/ Legally Authorized Representative

Date

Printed Name of Participant/ Authorized Representative

*Signature of Witness (When applicable)

Printed Name of Witness

Time

Date

Time

Signature of Person Obtaining Consent

Printed Name of Person Obtaining Consent

** Use when participant has had consent form read to them (i.e.,
translated into foreign language).

Date

Time
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APPENDIX C
List of Additional Questions pertaining to Symptoms of Psychological Disturbance

1. Have you had any thoughts of suicide or harming yourself in the past two weeks?
2. Do you hear or see things other people don't?
3. Do you still take pleasure in activities you find interesting?
4. Have you noticed a significant (i.e., >5%) change in your body weight in the last
two weeks?
5. Do you have crying spells for no apparent reason (i.e., find yourself crying but
don't know why)?
6. Have you been feeling more sad than usual over the last two weeks?
7. Have you noticed a decrease (e.g., sleep only about 3 hours and feel rested) in
your need for sleep in the last week?
8. Have you felt more restless or on-edge in the past 6 months?
9. Have you felt like your thoughts were racing faster than you could get them out in
the past week?
10. Have you taken on any large projects (i.e., painting the house, tiling the kitchen)
in the past week and worked on them endlessly without feeling very hungry or
tired?
11. Have you recently noticed times when your heart was racing or pounding for no
apparent reason?
12. Have you recently experienced periods of excessive sweating for no reason?
13. Have you recently experienced periods of excessive shaking or trembling for no
apparent reason?
14. Have you recently experienced any physical symptoms such as nausea, pain in
your chest, shortness of breath, light-headed or dizziness for no apparent
reason?
15. Do you ever have thoughts, not just about real-life problems, that you just can't
seem to get out of your head?
16. Do these thoughts cause you to worry excessively?
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17. Have you had difficulty falling or staying asleep in the past two weeks because
you very tense or worried?
18. Are there any behaviours you do regularly (>4 times/day), for example, washing
your hands or checking to make sure the stove is turned off?
19. Have you noticed you have been more physically tense in the last 6 months?
20. Have you noticed you have been more irritable than usual in the last 6 months?
21. Have you noticed a drastic increase in the amount you sleep in the last 2 weeks?
22. Have you found it difficult to concentrate on things you had to do in the last 2
weeks?
23. Have you felt a significant loss of energy in the past two weeks?

Decision Rules
Discontinue if the patient answers "yes" to items 1 or 2.
Discontinue if the patient answers "yes" to at least five of items 3, 4, 5, 6, 21, 22,
and 23.
Discontinue if the patient answers "yes" to at least two of items 7,9, and 10.
Discontinue if the patient answers "yes" to at least two of items 11,12,13, and
14.
Discontinue if the patient answers "yes" to at least two of items 15,16, and 18.
Discontinue if the patient answers "yes" to at least three of items 8,17,19, 20, 22, or
23.
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.83
.91

StroopWord

Stroop Interference

.17-.56

.17-.56

.17-.56
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Stroop Interference = Stroop Colour-Word trial time to completion.

Stroop Word = Stroop Words trial time to completion.

Stroop Dot = Stroop Dots trial time to completion.

TMT Part B = Trail Making Test Part B time to completion.

TMT Part A = Trail Making Test Part A time to completion.

WMS-III = Wechsler Memory Scale, 3rd Edition.

WAIS-III = Wechsler Adult Intelligence Scale, 3rd Edition.

Total 1-5 = Total words recalled trials 1-5.

RAVLT = Rey Auditory Verbal Learning Test.

scores respectively.

Numbers in parentheses represent the intercorrelations between Logical Memory I and II scores and Verbal Paired Associate I and II

test-retest reliabilities are reported due to the timed nature of these tests.

For Coding, Symbol Search, TMTA, TMTB, and Stroop Dots, Words and Interference only

Note. Sources of the information in this appendix are listed in Appendix E.

.90
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Ryan et al. (as cited in

Digit Span

WAIS-III

Recognition
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Total 1-5
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APPENDIX E
Published sources of psychometric data for tests used in the battery

Symbol Search (Wechsler, 1997).

subtests but is the WISC-III for

Criterion is the WAIS-R for all

cited in Schmidt, 1996)

Memory subtest. Malec et al. (as

Convergent Validity
Criterion is the WMS-III Logical
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data) (as cited in Strauss,
Sherman, & Spreen, 2006)

Stroop Word

Stroop

WMS-III = Wechsler Memory Scale, 3rd Edition

WISC-III = Wechsler Intelligence Scale for Children, 3 rt Edition.

WAIS-R = Wechsler Adult Intelligence Scale, Revised.

WAIS-III = Wechsler Adult Intelligence Scale, 3rd Edition.

Total 1-5 = Total words recalled trials 1-5.

Note. RAVLT = Rey Auditory Verbal Learning Test.

Interference

Bullock et al. (unpublished

Sherman, & Spreen, 2006)

Pineda et al. (as cited in Strauss,

the three subtests of the Stroop.

Intercorrelation ranges between

Sherman, & Spreen, 2006)

Spreen, 2006)

Stroop Dot

al. (as cited in Strauss,

Royan et al. (as cited in Strauss,

cited in Strauss, Sherman, &

TMT Part B

Spreen, 2006)

cited in Strauss, Sherman, &

London Test. Hanes et al. (as

completion on the Tower of

Criterion is number of trials to

Sherman, & Spreen, 2006)

Serial Attention Test. Royan et

Intercorrelations with each other.

Dikmen et al. (as

Spatial Span
TMTPartA

Criterion is the Paced Auditory

(Wechsler, 1997).

Memory

Intercorrelation between logical
memory I and II subtests

Wechsler(1997)
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Logical

WMS-III
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TMT Part B= Trail Making Test Part B.

TMT Part A = Trail Making Test Part A.
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